Withdrawal of renin-angiotensin system inhibitors' effect on estimated glomerular filtration rate in adults with advanced kidney disease: the STOP-ACEi RCT

Sunil Bhandari, Samir Mehta, Arif Khwaja, John Cleland, Natalie Ives, Elizabeth Brettell, Marie Chadburn and Paul Cockwell for the STOP-ACEi Trial Investigators

Withdrawal of renin-angiotensin system inhibitors' effect on estimated glomerular filtration rate in adults with advanced kidney disease: the STOP-ACEi RCT

Sunil Bhandari,[1]* Samir Mehta,[2] Arif Khwaja,[3] John Cleland,[4] Natalie Ives,[2] Elizabeth Brettell,[2] Marie Chadburn[2] and Paul Cockwell[5] for the STOP-ACEi Trial Investigators

[1]Department of Renal Medicine, Hull University Teaching Hospitals NHS Trust, and Hull York Medical School, East Yorkshire, UK
[2]Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
[3]Sheffield Kidney Institute, Sheffield, UK
[4]National Heart & Lung Institute, Imperial College London, London, UK
[5]Department of Renal Medicine, Queen Elizabeth Hospital, Birmingham, UK

*Corresponding author

Disclosure of interests

Efficacy and Mechanism Evaluation

> **Criteria for inclusion in the *Efficacy and Mechanism Evaluation* journal**
> Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in humans and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

This report

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the EME programme or the Department of Health and Social Care.

Abstract

Withdrawal of renin-angiotensin system inhibitors' effect on estimated glomerular filtration rate in adults with advanced kidney disease: the STOP-ACEi RCT

Sunil Bhandari[ID],[1*] Samir Mehta[ID],[2] Arif Khwaja[ID],[3] John Cleland[ID],[4] Natalie Ives[ID],[2] Elizabeth Brettell[ID],[2] Marie Chadburn[ID][2] and Paul Cockwell[ID][5] for the STOP-ACEi Trial Investigators

[1]Department of Renal Medicine, Hull University Teaching Hospitals NHS Trust, and Hull York Medical School, East Yorkshire, UK
[2]Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
[3]Sheffield Kidney Institute, Sheffield, UK
[4]National Heart & Lung Institute, Imperial College London, London, UK
[5]Department of Renal Medicine, Queen Elizabeth Hospital, Birmingham, UK

*Corresponding author sunil.bhandari@nhs.net

Background: Renin–angiotensin system inhibitors, both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, slow progression of mild and moderate chronic kidney disease. However, some evidence suggests that discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease might increase estimated glomerular filtration rate or slow its decline.

Objective: To test the hypothesis that stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, or a combination of both, compared with continuing these treatments, improves or stabilises kidney function in patients with progressive stages 4 or 5 chronic kidney disease based on assessment of kidney function using the modification of diet in renal disease four-variable estimated glomerular filtration rate at 3 years, follow-up.

Setting: Thirty-seven UK hospitals with kidney services.

Design: An investigator-led multicentre open-label, randomised controlled trial of 411 participants with advanced (stage 4 or 5) progressive chronic kidney disease.

Participants: Adult patients with advanced (estimated glomerular filtration rate < 30 ml/minute/1.73 m^2) and progressive chronic kidney disease who were receiving either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, or a combination of both.

Interventions: Participants were randomised in a 1 : 1 ratio using a centralised internet-based system to either discontinue renin–angiotensin system inhibitors (*n* = 206) or continue renin–angiotensin system inhibitors (*n* = 205).

Main outcome measures: The primary outcome was the estimated glomerular filtration rate at 3 years; measurements of estimated glomerular filtration rate made after commencing kidney replacement therapy were excluded. Secondary outcomes included development of end-stage kidney disease or starting kidney replacement therapy, a composite of either a > 50% decline in estimated glomerular filtration rate or commencement of kidney replacement therapy (including end-stage kidney disease), cystatin C, hospitalisations, blood pressure, exercise capacity and quality of life. Cardiovascular events, death and safety were recorded.

Results: At 3 years, the least-squares mean (± standard error) estimated glomerular filtration rate was 12.6 ± 0.7 ml/minute/1.73 m^2 in the discontinuation group and 13.3 ± 0.6 ml/minute/1.73 m^2 in the continuation group [difference −0.7, 95% confidence interval (−2.5 to 1.0; p = 0.42)] with a negative value favouring the continuation group. The treatment effect did not differ (heterogeneity) when data were analysed by the pre-specified subgroups. End-stage kidney disease or kidney replacement therapy occurred in 128 (62%) and 115 (56%) participants randomised to the discontinue and continue renin–angiotensin system inhibitor groups, respectively (hazard ratio 1.28, 95% confidence interval 0.99 to 1.65). The numbers of cardiovascular events and deaths observed were similar for those randomised to discontinue (108 events and 20 deaths) or continue (88 events and 22 deaths) renin–angiotensin system inhibitors.

Limitations: Non-white ethnic backgrounds were poorly represented, limiting the generalisability of our findings. The open-label nature of the trial may have affected clinical care and subjective end points, such as quality of life and exercise capacity. We only included patients who were receiving renin–angiotensin system inhibitors at the time of randomisation, thus excluding those who had already discontinued these agents.

Conclusions: Discontinuing renin–angiotensin system inhibitors in advanced and progressive chronic kidney disease does not cause a clinically relevant change in estimated glomerular filtration rate or difference in its long-term decline.

Future work: Future work should focus on updating clinical guidelines. Further analyses, in addition to the prespecified analyses, may be undertaken if new estimated glomerular filtration rate equations are introduced into clinical practice. Subgroup analysis by kidney disease aetiology and gender may be undertaken to look for potential differences in outcome in specific groups.

Trial registration: This trial is registered as STOP ACEi EudraCT Number, 2013-003798-82; ISRCTN62869767.

Contents

CONTENTS

List of tables

List of figures

List of supplementary material

Report Supplementary Material 1 Supplementary Material 1

Supplementary material can be found on the NIHR Journals Library report page (https://doi.org/10.3310/TTMC6210).

Supplementary material has been provided by the authors to support the report and any files provided at submission will have been seen by peer reviewers, but not extensively reviewed. Any supplementary material provided at a later stage in the process may not have been peer reviewed.

List of abbreviations

ACE	angiotensin-converting enzyme	ITT	intention-to-treat
ACEi	angiotensin-converting enzyme inhibitor	KDQoL	kidney disease quality of life
AE	adverse event	KRT	kidney replacement therapy
ARB	angiotensin receptor blocker	LS-Mean	least-squares mean
BCTU	Birmingham Clinical Trials Unit	MAP	mean arterial pressure
BP	blood pressure	MDRD	modification of diet in renal disease
CI	confidence interval	NICE	National Institute for Health and Care Excellence
CKD	chronic kidney disease		
CKD-EPI 2009	Chronic Kidney Disease Epidemiology Collaboration 2009	NIHR	National Institute for Health and Care Research
CRF	case report form	PCR	protein-to-creatinine ratio
CTCAE	common terminology criteria for adverse events	PI	principal investigator
		PIS	participant information sheet
CV	cardiovascular	RAS	renin–angiotensin system
DMEC	Data Monitoring and Ethics Committee	RCT	randomised controlled trial
		RR	relative risk
eGFR	estimated glomerular filtration rate	SAE	serious adverse event
		SD	standard deviation
ESA	erythropoietin stimulating agent	SE	standard error
		SUSAR	suspected unexpected serious adverse reaction
ESKD	end-stage kidney disease		
GFR	glomerular filtration rate	TMG	Trial Management Group
GP	general practitioner	TSC	Trial Steering Committee
HR	hazard ratio	uPCR	urinary protein-to-creatinine ratio

Plain language summary

Drugs called angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, together known as renin–angiotensin system inhibitors, are used to treat high blood pressure, slow worsening kidney function and lower the risk of kidney failure (known as end-stage kidney disease which requires treatment with dialysis or kidney transplantation) in patients with early chronic kidney disease. However, we did not know if patients treated with renin–angiotensin system inhibitors and who have progressed to more advanced chronic kidney disease (stage 4 or 5) should stop or continue renin–angiotensin system inhibitors.

To determine whether stopping renin–angiotensin system inhibitors in people with advanced chronic kidney disease leads to an improvement or stabilisation of kidney function required a study comparing the outcomes of people who had had these drugs stopped with a group who continued these drugs (the STOP-angiotensin-converting enzyme inhibitors trial). We recruited 411 participants with advanced chronic kidney disease who were receiving renin–angiotensin system inhibitors from 37 kidney units in the UK, and randomly (like flipping a coin) allocated them to either stop or continue renin–angiotensin system inhibitors.

We then compared kidney function between the two groups at 3 years. We also assessed whether stopping or continuing renin–angiotensin system inhibitors had an influence on the development of end-stage kidney disease or need for kidney replacement therapy, the number of hospitalisations, blood pressure, quality of life and physical function. We collected data on safety outcomes including death and heart-related events (such as heart attacks).

The results of the trial showed no difference in kidney function at 3 years. The number of participants requiring dialysis, or a kidney transplant was also similar, as was the quality of life and physical function between the groups. Deaths and the number of heart events were similar in both groups.

This research suggests that there is no benefit in stopping renin–angiotensin system inhibitors in patients with advanced chronic kidney disease.

Scientific summary

Background

Renin–angiotensin system (RAS) inhibitors, both angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), slow the progression of mild and moderate chronic kidney disease (CKD). However, some evidence suggests that discontinuation of RAS inhibitors in patients with advanced CKD might increase estimated glomerular filtration rate (eGFR) or slow its decline.

Primary objective

To test the hypothesis that discontinuing ACEi or ARB treatment, or a combination of both, compared with continuing on these treatments, improves or stabilises kidney function in patients with progressive stage 4 or stage 5 CKD based on assessment of kidney function using the modification of diet in renal disease (MDRD) four-variable eGFR at 3 years follow-up.

Secondary objectives

To test whether in each of the randomised groups.

Clinical outcomes

- The number of participants starting kidney replacement therapy (KRT) (dialysis or transplantation) or sustaining a > 50% decline in eGFR differs.
- There is a difference in the time taken to reach end-stage kidney disease (ESKD) or need for KRT.
- Hospitalisation rates from any cause are different.
- Participant quality of life and well-being [measured using the kidney disease quality of life (KDQoL)-SF™ v1.3 questionnaire] differs.
- Participant physical function (measured using the 6-minute walk test) differs.
- Withdrawal of these treatments does not cause excess harm [e.g. increased cardiovascular (CV) events such as heart failure, hypertension, myocardial infarction, stroke] and is not associated with an increase in adverse effects.
- Participant survival in each group is similar.
- Blood pressure (BP) control is the same.
- Cystatin-C levels differ.

Mechanistic outcomes

- There is a change in urine protein excretion [urinary protein-to-creatinine ratio (uPCR)].
- Discontinuation of ACEi/ARB affects haemoglobin concentration.
- Discontinuation of ACEi/ARB affects the requirement for erythropoietin stimulating agents.

Methods

An investigator-initiated, multicentre, open-label randomised trial where people with advanced and progressive CKD (eGFR < 30 ml/minute/1.73 m^2) were randomised to either discontinue or continue RAS inhibitors, and then followed up every 3 months for 3 years.

Patients underwent screening at 39 centres in the UK. Adults (≥ 18 years of age) with stage 4 or stage 5 CKD (eGFR, < 30 ml/minute/1.73 m^2 of body-surface area) were eligible to participate in the trial if they were not receiving dialysis and had not undergone kidney transplantation. All eligible patients were required to have had a decrease of more than 2 ml/minute/1.73 m^2 per year in the eGFR during the previous 2 years and to have been receiving treatment with an ACEi, an ARB, or both for more than 6 months. We calculated the eGFR using the four-variable equation used in the MDRD study, as updated in 2005 (MDRD$_{175}$). Exclusion criteria included uncontrolled hypertension or a history of myocardial infarction or stroke within the previous 3 months. All the patients provided written informed consent.

Patients were randomly assigned in a 1 : 1 ratio to either discontinue or continue RAS inhibitors. Randomisation used a centralised internet-based system with minimisation to ensure balance between groups for the following variables: age (< 65 or ≥ 65 years), eGFR (< 15 or ≥ 15 ml/minute/1.73 m^2), diabetes (type 1, type 2, or none), mean arterial pressure (< 100 or ≥ 100 mmHg) and proteinuria [protein-to-creatinine ratio (PCR), < 100 or ≥ 100 mg/mmol]. In the group that discontinued RAS inhibitor, any guideline-recommended antihypertensive agent other than a RAS inhibitor could be used to control BP. In the group that continued RAS inhibitors, the responsible clinician chose the agent and dose of the RAS inhibitor and could combine it with any other guideline-recommended antihypertensive agent.

The primary outcome was the eGFR at 3 years as calculated according to the MDRD$_{175}$ four-variable equation. Secondary outcome measures included the time until the development of ESKD or initiation of KRT; a composite of a decrease of more than 50% in the eGFR, the development of ESKD, or the initiation of KRT; hospitalisation for any cause; measures of cystatin C and BP; quality of life (as measured on the KDQoL 36-Item Short Form Survey, version 1.3); exercise capacity (as assessed by the 6-minute walk test); and CV events and death. At the time of this report, the transfer and processing of samples for cystatin C measurement had not yet occurred, so the results are not provided here. Secondary mechanistic outcomes included measures of haemoglobin and urinary protein excretion (PCR).

The trial aimed to recruit 410 patients (205 patients in each trial group) which would provide 80% power to determine a minimum relevant between-group difference in the eGFR of 5 ml/minute/1.73 m^2 (alpha level of 0.05), assuming an attrition rate of 20%. This difference represents an effect size of 0.31, with a standard deviation of 16 ml/minute/1.73 m^2.

The analyses were based on the intention-to-treat principle and were adjusted for the minimisation variables and baseline values. A repeated-measures, mixed-effects linear regression model was used to estimate the between-group difference in eGFR at 3 years. Any measurements of eGFR that were made after patients had initiated dialysis or undergone kidney transplantation were excluded from the primary analysis. To examine the effect of data that were not missing at random, we performed sensitivity analyses by fitting pattern-mixture and joint models for the primary outcome. We also repeated analyses for the primary outcome with the use of two other four-variable equations for the eGFR calculation: the Chronic Kidney Disease Epidemiology Collaboration 2009 equation and the MDRD$_{186}$ equation. Continuously distributed secondary outcomes, such as BP, were analysed using the same methods as per the primary analysis, but data were not censored at the time of initiation of KRT. Categorical (dichotomous) secondary outcomes were analysed with the use of a Poisson regression model with robust standard errors (SEs) to estimate the relative risk (RR) and 95% confidence interval (CI). A Cox proportional-hazards model was used to calculate hazard ratios (HRs) and 95% CIs for time-to-event outcomes, such as the development of ESKD or the initiation of KRT. Categorical safety outcome

measures (i.e. hospitalisation and serious adverse events) were summarised as the percentage of patients with these events. Data collection for kidney outcomes did not distinguish between ESKD and kidney-replacement outcomes (i.e. both outcomes used the same end-point code), although investigators could note the specific outcome. Prespecified subgroup analyses were performed only for the primary outcome according to the minimisation variables. Time and subgroup were included in the model to allow for the possibility of differential changes over time within subgroups, time according to subgroup and the three-way interaction among the variables of treatment, time and subgroup. Although all data were included in the regression models for the subgroup analyses, only estimates of differences at 3 years are presented. All analyses were performed with the use of SAS software, version 9.4 (SAS Institute), and Stata software, version 17 (StataCorp).

Results

At 3 years, among the 411 patients who underwent randomisation, the least-squares mean (LS-Mean) (±SE) eGFR was 12.6 ± 0.7 ml/minute/1.73 m^2 in the discontinuation group and 13.3 ± 0.6 ml/minute/1.73 m^2 in the continuation group (difference −0.7, 95% (CI −2.5 to 1.0; $p = 0.42$) with a negative value favouring the continuation group.

End-stage kidney disease or the initiation of KRT occurred in 128 patients (62%) in the discontinuation group and in 115 patients (56%) in the continuation group (HR 1.28, 95% CI 0.99 to 1.65). The number of patients with > 50% decline in eGFR or need to start KRT (including ESKD) was 140/206 (68%) in the discontinue RAS inhibitor group compared to 127/202 (63%) in the continue RAS inhibitor group; RR 1.07, 95% CI 0.94 to 1.22.

The number of hospitalisations were similar between the groups; 414 in the stop RAS inhibitor group versus 413 in the continue RAS inhibitor group. The difference in LS-Mean at 3 years for systolic BP was 0 mmHg, 95% CI −4 to 5 mmHg. The results were similar for diastolic BP; 0 mmHg, 95% CI −2 to 3 mmHg. Adverse events were similar in both the discontinuation group and continuation group with respect to CV events (108 vs. 88) and deaths (20 vs. 22).

Conclusions

Our STOP-ACEi trial showed that discontinuing RAS inhibitors for patients with advanced and progressive CKD does not lead to a clinically relevant change in eGFR or difference in the rate of long-term decline in eGFR, overall or in pre-specified subgroups by age, severity of CKD, diabetes, proteinuria or BP.

Numerically more patients who discontinued RAS inhibitors had progression to ESKD or need for KRT, so a larger trial might have shown an advantage to continuing with RAS inhibition.

The rate of CV events and death was similar.

Systolic and diastolic BP and proteinuria were greater over the first year of follow-up in those randomised to discontinue RAS inhibitors but there was little difference, thereafter, reflecting initiation of antihypertensive agents other than RAS inhibitors.

No differences in quality of life or exercise capacity were observed for those who discontinued or continued RAS inhibitors.

Our trial lacked sufficient power to investigate the effect of withdrawing RAS inhibitors on CV events or mortality. However, because our trial suggests that there is no advantage in discontinuing RAS inhibitors

from the perspective of kidney function, there is little rationale to conduct a larger randomised trial to investigate CV safety.

Future work

Future work should initially focus on updating clinical guidelines in the UK and potentially worldwide. Further analyses, in addition to the prespecified analyses, may be undertaken if new eGFR equations are introduced into routine clinical practice such as the National Institute for Health and Care Excellence recommended removal of black ethnicity correction factor from the eGFR equation. Consideration of subgroup analysis by aetiology of kidney disease and gender will be considered to look for any potential differences in outcome in specific groups which might warrant future studies.

Trial registration

This trial is registered as STOP ACEi EudraCT Number, 2013-003798-82; ISTRCTN62869767.

Funding

Chapter 1 Introduction

Scientific background

Many different diseases may damage the kidneys and most result in a progressive decline in kidney function with time, known as chronic kidney disease (CKD). Some patients with CKD may progress to end-stage kidney disease (ESKD) requiring dialysis and/or kidney transplantation to prolong life and improve clinical outcomes. The progressive nature of kidney damage, irrespective of cause, is a major global challenge. Despite an increasing number of treatments that slow the decline of kidney function with time, the numbers of patient with ESKD will continue to increase.

Chronic kidney disease affects 9.1% globally and up to one in seven people in the UK.[1] The underlying common pathogenic process is progressive renal scarring as evidenced by tubulo-interstitial fibrosis and glomerulosclerosis, irrespective of the underlying causative disease, which most commonly is diabetes and/or hypertension. CKD has serious implications for those affected and is associated with a high prevalence of cardiovascular (CV) disease, early mortality and high economic cost.[1] The risk of adverse event (AEs) is directly related to the severity of the CKD; advanced CKD (stage 4 or stage 5) is associated with a 2.5-fold increased risk of death, and an up to 50-fold increased risk of kidney failure, as defined by requirement for dialysis treatment, compared to that of age-matched individuals with normal kidney function.[2–5] Furthermore, the presence of advanced CKD has a major negative impact on a range of other outcomes including quality of life.[6,7]

A high proportion of the healthcare budget is spent on people with kidney disease. The most explicit example of this being the cost of dialysis treatment for ESKD, which is ~£32,000/year/patient.[4] This cost is in a patient group with poor health and poor quality of life, a 10–15%/year mortality risk and a substantial increase in hospitalisations.[1,5,6] The management of people requiring dialysis currently requires approximately 3% of the total NHS budget.[7] For CKD overall the economic costs are profound. A recent economic analysis, based on Public Health England data, projected that by 2025, CKD will cost £11.4 billion for every 1 million people with diabetes. Consequently, there are major benefits associated with slowing the progression of CKD to ESKD for patients, their families and for the healthcare systems in which they are managed. Treating high blood pressure (BP) is the most important intervention that can slow the progression of CKD. Some people with CKD, especially those with proteinuria, gain additional protection from angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs).[8–11] There is also benefit of use post myocardial infarction and for other CV events, an important consideration given the high CV risk to this patient group.[12]

There is some evidence that in people with advanced CKD estimated glomerular filtration rate (eGFR < 30 ml/minute/1.73 m^2; stage 4 or stage 5) who are progressing towards ESKD and are receiving treatment with renin–angiotensin system (RAS) inhibitors, discontinuing these drugs may lead to a stabilisation or improvement of kidney function and decrease or delay the need for dialysis treatment.[13] To date, the research on this has been limited to a small randomised single-centre trial in Asia,[14] post hoc analyses in other studies,[15,16] observational studies of RAS inhibitors across all eGFRs[17] and analysis from registry studies.[18]

A meta-analysis[19] reporting an association between discontinuing RAS inhibitors and stabilisation of kidney function, however, also reported a potential increased risk of major CV events and death in people with low eGFR values in whom RAS inhibitors were discontinued. This was not supported by Registry data suggesting no benefit on kidney function.[20] Furthermore, Molnar and colleagues analysed a representative US veterans cohort with non-dialysis CKD consisting of 141,413 participants of which 26,051 had received treatment with RAS inhibitors. The population was 97% male with a mean age of 74.8 ± 19.8 years, with a mean [± standard deviation (SD)] eGFR of 52 ± 16 ml/minute/1.73 m^2 and only

6% of patients in CKD stage 4 or stage 5 category. They found an association with reduced all-cause mortality in the RAS inhibitor group, but only 10% remained on treatment throughout all follow-up visits.[17] Cheng *et al.*, in a meta-analysis, separately evaluated the effects of RAS inhibitors on all-cause mortality, CV deaths, and major CV events in patients with diabetes mellitus.[21] In their final analysis of 20 eligible studies (with 25,544 participants), they found a 13% reduction in all-cause mortality [hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.78 to 0.98], 17% in CV death (HR 0.83, 95% CI 0.70 to 0.99), 21% in CV events (HR 0.79, 95% CI 0.65 to 0.95) and 19% in heart failure (HR 0.81, 95% CI 0.71 to 0.93), in patients receiving ACEi compared to placebo. For studies where patients received ARBs, there were 11 eligible studies (with 17,334 participants), and there was significant association with a reduction in heart failure events (HR 0.70, 95% CI 0.59 to 0.82), but not in other CV end points. Notably, there have been no clinical trials of the impact of RAS inhibitors on progression of kidney disease where patients are randomised at an eGFR of < 30 ml/minute/1.73 m^2, and this remains a much-understudied cohort of patients in historical randomised clinical trials.[22,23]

Clinical data

Irrespective of the underlying cause of CKD, the use of RAS inhibitors for the control of BP (hypertension is an almost universal complication and co-factor in the progression of CKD), and minimisation of urinary protein excretion (a surrogate for glomerular hypertension and risk of progressive CKD) has a central role in clinical practice in slowing the progression of CKD in patients with mild to moderate CKD. The rationale is that RAS inhibitors reduce intraglomerular pressure over and above the effect of these agents on systemic BP. High intraglomerular pressure through direct effects on the glomerular vasculature leads to changes in intraglomerular extracellular matrix and the development of glomerulosclerosis and tubule-interstitial scarring through proteinuria and other mechanisms.

Lewis and others demonstrated that RAS inhibitors reduced the doubling time of creatinine in patients with type I and type II diabetes over a 3-year period.[8-10] Further studies have shown that RAS inhibitors reduced the progression of kidney disease in patients with no diabetes.[14,24-27] Data from the HOPE, LIFE and ALLHAT studies have confirmed the benefit of ACEi use in mild CKD.[28-30] Ruggenenti *et al.* in an analysis of 322 patients with non-diabetic CKD at varying stages of disease randomly assigned to either ramipril or conventional treatment, found that the renoprotective effects were maximised when ACEi therapy was started earlier in the course of the disease [i.e. glomerular filtration rate (GFR) > 50 ml/minute/1.73 m^2], but suggested that therapy should be offered to all patients with CKD, even those with a GFR between 10 and 30 ml/minute/1.73 m^2.[15] In 2006, Hou *et al.* examined a Chinese population of 422 patients with non-diabetic CKD and placed them into one of two groups based upon their baseline serum creatinine levels. Patients in group 1 (serum creatinine between 133 and 265 µmol/l; *n* = 104) received 20 mg of benazepril per day and patients in group 2 (serum creatinine between 274 and 442 µmol/l) were randomised to 20 mg of benazepril per day (*n* = 112) or placebo (*n* = 112). Participants were followed up for a mean of 3.4 years.[14] The authors reported a statistically significant, 43% decrease in the composite end point of doubling of serum creatinine level, progression to ESKD, or death, in the benazepril group compared to placebo. In 2006, a Cochrane Review explored the use of RAS inhibitors in preventing the progression of kidney disease in patients with diabetes.[31] The review included 49 studies with 12,067 patients at all stages of kidney disease. It included studies that compared ACEi or ARBs to placebo and studies that directly compared ACEi and ARBs. The authors found that both ACEi and ARBs improved kidney outcomes (ESKD, doubling of creatinine, prevention of progression of microalbuminuria to macroalbuminuria, remission of microalbuminuria to normoalbuminuria).[31] Further, when compared to placebo, use of ACEi at maximum tolerated doses appeared to prevent death in patients with diabetic kidney disease [relative risk (RR) 0.78, 95% CI 0.61 to 0.98]. These mortality data were not found with ARBs. The authors however cautioned against the conclusion that RAS inhibitors prevent the progression of CKD and suggested that the beneficial initial effect seen may be due to their anti-proteinuric effects, and that there was little robust evidence of benefit in advanced CKD and that the conclusions were based mainly on composite end points.

These studies suggesting that RAS inhibitors are renoprotective, and potentially cardioprotective, in patients with CKD have led to guideline recommendations where the evidence base for RAS inhibitors in patients with mild to moderate kidney disease and with proteinuria and/or diabetes has been interpreted as also applying to advanced CKD.[32] However, the rigour of some of these studies, which did not dissect the renoprotective effects that are specific for RAS inhibitors from their antihypertensive effect, is now being questioned by many nephrologists.

A detailed assessment of published data from the REIN study indicated a limited effect of ACEi on GFR progression despite a large difference in composite end points including doubling of serum creatinine.[15,24] This may relate, in part, to the effects of ACEi on reducing glomerular capillary pressure and increasing glomerular blood flow through efferent arteriole vasodilatation, leading to a reduction in filtration fraction and hence proteinuria. ACEi should lead to increased peritubular circulation secondary to improved efferent arteriolar blood flow. However, the increase in peritubular capillary flow may affect proximal tubular transport of proteins and creatinine via effects on the organic cationic transporters, leading to increased tubular creatinine secretion, a fall in serum creatinine and hence an apparent rise in GFR.[33]

While these principles may hold for mild to moderate CKD, the biological actions and clinical effects in advanced CKD are unknown. Renoprotection from RAS inhibitors may be lost in more advanced disease where significant ischaemic nephropathy is present and there is loss of peri-tubular capillary vasculature. This hypothesis is supported by reports in patients with CKD both with and without diabetes indicating that RAS inhibitors may accelerate kidney progression.[11,34] It is possible that in more advanced CKD the intrarenal haemodynamic effects of RAS inhibitors may decrease the time to ESKD. Furthermore, combined ACEi/ARB treatment has been shown in one large study to worsen kidney outcomes in patients at high CV risk.[35]

A meta-analysis of nine randomised controlled trials (RCTs) (n = 9797 participants) of at least 6 months' duration in adult patients with diabetes and non-dialysis-dependent CKD stage 3 to stage 5 examined single RAS inhibitor versus placebo or an alternative antihypertensive agent.[36] The authors found no difference between the RAS inhibitors group and control group regarding all-cause mortality (RR 0.97, 95% CI 0.85 to 1.1), CV mortality (RR 1.03, 95% CI 0.75 to 1.41) and AEs (RR 1.05, 95% CI 0.89 to 1.25). There was, however, a trend towards a lower risk of the composite end point of need for KRT/doubling of serum creatinine (RR 0.81, 95% CI 0.70 to 0.92) in the RAS inhibitor group versus the control group, but this was dependent on the selected outcome measure.[36] (Copyright © 2015, Oxford University Press)

Finally, initiation of RAS inhibitors therapy may cause acute reductions in eGFR, hyperkalaemia and episodes of acute kidney injury.[37,38] Therefore, it is unclear whether the risks may outweigh the benefits as CKD progresses to an eGFR < 30 ml/minute/1.73 m² and whether RAS inhibitors should be discontinued at this level of kidney function. As discussed above, this group of patients is under-represented in clinical trials and this is one of a number of clinically important questions for patients with advanced CKD that have not to date been addressed by a RCT.[22] The particular importance of carrying out a rigorous clinical trial on RAS inhibitors in advanced CKD is the major uncertainty in this area, with data from observational studies raising concerns that some patients may sustain worse clinical outcomes if they continue RAS inhibitors when they progress to advanced CKD.

An observational study by Ahmed and colleagues reported that RAS inhibitor withdrawal in 52 patients with advanced CKD led to an overall mean increase in eGFR of 10 ml/minute/1.73 m² over 12 months (16.4–26.6 ml/minute/1.73 m²), and an increase or stabilisation in eGFR in all but 4 patients.[13] A modest increase in BP was observed, but there was no increase in CV events.[13] Furthermore, data from a retrospective cohort study highlighted the challenges of RAS inhibitors in patients with CKD.[39] Evaluation of risk factors for adverse drug events found factors such as hyperkalaemia and kidney

impairment as stated reasons for discontinuation of RAS inhibitors.[39] In this study, of 2225 outpatients administered an ACEi, 19% of the initial group discontinued ACEi therapy due to AEs.

The impact of RAS inhibitors on kidney outcomes in advanced CKD should always be considered through the prism of CV disease. The close interaction of kidney and heart is critical to survival and there is a huge array of traditional and kidney specific risk factors for CV disease that makes this a complex area of study. For example, the risk factors for poor CV disease outcomes in the general population and mild to moderate CKD are associated with better outcomes in advanced CKD.[40,41] Furthermore, CV events are more common in dialysis than pre-dialysis patients suggesting the increased importance of avoiding dialysis therapy, which accelerates CV risk.[42,43] There are no studies assessing the benefits of RAS inhibitors therapy in CV risk reduction in advanced non-dialysis CKD. Observational studies suggest lower CV risk at all levels of eGFR with the use of RAS inhibitors.[17,44] Several randomised controlled studies in dialysis patients have shown increased CV events with use of ACEi.[45,46] A prospective cohort study from Taiwan examined 28,497 patients with hypertension, a baseline serum creatinine more than 520 µmol/l, and receiving erythropoietin stimulating agents (ESA), and compared outcomes in those receiving RAS inhibitors with those not receiving RAS inhibitors. At a median follow-up of 7 months, 70.7% of the cohort were receiving long-term dialysis, with a HR of 0.94 (95% CI 0.91 to 0.97) for receipt of dialysis and a HR of 0.94 (0.92 to 0.97) for a reduced composite of death or dialysis in patients receiving RAS inhibitors.[47]

Two observational studies reported differences in outcomes. In a study of 54,000 patients, Qiao and colleagues reported an increased risk of CV events and no impact on kidney function in those receiving RAS inhibitors.[20] They observed that continuing RAS inhibitors did not increase the risk of KRT (HR 1.19, 95% CI 0.86 to 1.65). However, there was a 20.4–45.3% discontinuation rate of RAS inhibitors across CKD stages 1 to stage 4 that after 5 years had increased to 46.8–83.7%.

A separate study examined 30,180 individuals registered in the Swedish Renal Registry, of which 10,254 were on RAS inhibitors of whom 1553 discontinued RAS inhibitors within 6 months.[18] The median age was 72 years, median eGFR 23 ml/minute/1.73 m^2 (range 18–29) and median urinary albumin : creatinine ratio (ACR) 35 mg/mmol (6–156). The results of the study showed that the estimated 5-year mortality risk was 40.9% (95% CI 38.9 to 42.8) among those who continued RAS inhibitor therapy, and 54.5% (95% CI 48.5 to 61.2) among those who stopped RAS inhibitor therapy. This thus corresponded to an absolute risk difference of 13.6% (95% CI 7.0 to 20.3) in the number of deaths for every 100 individuals and a 5-year restricted mean survival time difference of −3.6 months (95% CI −5.4 to −1.8). The 5-year risk of major adverse CV events was 47.6% (45.9–49.4) in the RAS inhibitor continuation group and 59.5% (53.8–66.1) in the discontinuing group, with an estimated 5-year absolute risk difference of 11.9 (5.7–18.6) events for every 100 individuals, and a 5-year restricted mean survival time difference of −33 months (−5.3 to −1.4). The impact on 5-year kidney replacement therapy (KRT) was 36.1% (34.7–37.7) in the continue group and 27.9% (23.5–32.5) in the discontinue group, giving an absolute risk reduction of −8.3 (−12.8 to −3.6) KRT events for every 100 individuals, with a 5-year restricted mean survival time difference of 0.8 months (−0.8 to 2.5) suggesting a lower absolute KRT risk in those discontinuing RAS inhibitor medications.

The main limitations of these studies are the lack of available information on the decision to stop RAS inhibitor therapy (clinician-related, patient-related, AE-related or other) and the residual confounding associated with observational studies.

A UK study of primary care records showed that there was a 56.8% discontinuation of RAS inhibitors at 5 years after initiation for patients with kidney disease.[48] In a study of 122,363 patients who began RAS inhibitors, cardiorenal outcomes were worse in those with a creatinine increase of 30% or more since

starting RAS inhibitors, with higher rates of ESKD, myocardial infarction, heart failure and death. This trend was also seen, to a lesser degree, in those with a smaller increase in creatinine values.[49,50]

The Stockholm Measurements Study, an observational cohort study involving older participants, reported that 26% of those who had started a RAS inhibitors discontinued the medication within 6 months.[51] This intervention was associated with 12% (6.9–18.3%) and 7.1% (1.8–13.2%) higher absolute risk for death and major CV events, respectively, over a 3-year period of follow-up. Again, these data do not account for confounding factors, inherent with observational studies. A further population-based study of 78,000 adults with non-dialysis-dependent CKD stage 3 to stage 5 also found that discontinuation of RAS inhibitors in those with hyperkalaemia (defined as a serum potassium of > 5.5 mmol/l) was associated with a higher risk of mortality and CV events.[52] Hence, whether RAS inhibitors provide a benefit in advanced and progressive CKD remains unclear.

Rate of change of glomerular filtration rate in clinical trials

A 2018 scientific workshop convened by the National Kidney Foundation, US Food and Drug Administration and European Medicines Agency evaluated the evidence for rate of change in GFR (i.e. GFR slope) as an alternative end point for kidney disease progression in RCTs,[53] and several recent studies and a meta-analysis have assessed CKD disease risk using kidney function loss as measured by rate of decline of eGFR (slope eGFR).[54,55] These studies have confirmed the utility of differences in eGFR slope as a surrogate for renal clinical outcomes as a means of assessing the impact of interventions with medication in clinical trials.[56–59] Inker *et al.* did a Bayesian individual patient meta-analysis of 47 studies with 60,620 participants and found that treatment effects on GFR slope from baseline to end of the study strongly predicted benefits on clinical outcomes.[54] The advantage of using this outcome is that it is a continuous variable which provides greater potential for discrimination of the ability of a novel therapy to demonstrate an effect on eGFR slope over time. Modelling analyses demonstrated that preservation of eGFR slope by ≥ 0.75 ml/minute/1.73 m^2/year over 3 years [median HR and 95% prediction interval: 0.69 (0.47 to 1.00)] predicts a clinically relevant delay of CKD progression with at least 96% probability.[52]

Kidney replacement therapy with dialysis remains an expensive and undesirable therapeutic option for patients with CKD and timing can impact mortality.[60] Mortality at 3 years is 25% and dialysis is associated with a poor quality of life.[61,62] Kidney transplantation, although associated with better clinical outcomes and quality of life, is not an option for many patients with ESKD, where significant comorbidity precludes transplantation, in particular for older patients (≥ 65 years old) who make up the majority with advanced CKD. There are few data on the effect of discontinuing RAS inhibitors on the CV event rate in this population. Indeed, no increased CV risk was noted in an observational cohort study from Ahmed *et al.*[13] but the potential risk of increased CV events needed further investigation in larger studies was an important consideration in trial design.

Summary

Trial evidence on the effectiveness and safety of RAS inhibitors discontinuation in advanced CKD is lacking; this is reflected in current guidelines which provide no specific instructions regarding RAS inhibitors in relationship to the severity of CKD.[63] The study by Ahmed *et al.*[13] suggests that withdrawal of RAS inhibitors in advanced CKD may be beneficial and based on the varied evidence; there is a need for a RCT for individuals with CKD who are receiving treatment with RAS inhibitors to compare the outcomes of a group who have RAS inhibitors to a group who continue.

Hypothesis

Does a strategy of discontinuing RAS inhibitor in patients with advanced (stage 4 or stage 5) progressive CKD lead to stabilisation of or improvement in kidney function over a 3-year follow-up period, provided good BP control is maintained with other agents, compared to a strategy of continuing RAS inhibitor?[64] The trial population will comprise participants with advanced and progressive CKD (stage 4 or stage 5), where there is no evidence base for the efficacy of RAS inhibitors on slowing further progression of CKD.

Primary objective

Thus, to test whether discontinuing ACEi or ARB treatment, or a combination of both, compared with continuing on these treatments, improves or stabilises kidney function in patients with progressive stage 4 or stage 5 CKD based on assessment of kidney function using the modification of diet in renal disease (MDRD) four-variable eGFR at 3-year follow-up, we carried out a multicentre open-label randomised trial in patients with advanced and progressive CKD.

Secondary objectives

To test whether in each of the randomised groups:

Clinical outcomes

- The number of participants starting KRT or sustaining a > 50% decline in eGFR differs.
- There is a difference in the time taken to reach ESKD or need for KRT.
- Hospitalisation rates from any cause are different.
- Participant quality of life and well-being [measured using the kidney disease quality of life (KDQoL)-SF™ v1.3 questionnaire] differs.
- Participant physical function (measured using the 6-minute walk test) differs.
- Withdrawal of these treatments does not cause excess harm (e.g. increased CV events such as heart failure, hypertension, myocardial infarction, stroke) and is not associated with an increase in adverse effects.
- Participant survival in each group is similar.
- Cystatin-C levels differ.
- BP control is the same.

Mechanistic outcomes

- There is a change in urine protein excretion [urinary protein-to-creatinine ratio (uPCR)].
- Discontinuation of ACEi/ARB affects haemoglobin concentration.
- Discontinuation of ACEi/ARB affects the requirement for ESA.

The results of this trial will provide evidence as to whether RAS inhibitors should be discontinued or continued in patients with advanced and progressive CKD. The study also included assessment of clinically relevant parameters (e.g. anaemia) and clinical outcomes including hospitalisation rates, physical function and quality of life. It was also designed to report on CV events, for which evidence is currently lacking. It was designed to assess if the benefits stopping RAS inhibitors outweigh the risk. The study should provide robust evidence to direct future guidelines and, if the study does not give a definitive answer, provide the basis for a larger RCT with a hard end point (death).

Chapter 2 Methods

Trial design and oversight

This was an investigator-initiated, multicentre, prospective, randomised, open-label trial that compared discontinuing or continuing RAS inhibitor in patients with advanced and progressive stage 4 or stage 5 CKD. Details of the objectives, design and methods of the trial have been published.[64,65]

Ethics approval and research governance

The protocol (Appendix) was approved by relevant health authorities and institutional review boards. Leeds East Research Ethics Committee approved the protocol (13/YH/10394).

The study was prospectively registered STOP ACEi EudraCT Number, 2013-003798-82 and ISTRCTN 62869767.

Trial oversight was provided by a Trial Management Group (TMG) chaired by the chief investigator (Sunil Bhandari). The Birmingham Clinical Trials Unit (BCTU) co-ordinated and managed the trial.

An independent Trial Steering Committee (TSC) provided overall oversight and supervision on the conduct of the trial, and a data monitoring committee reviewed unblinded data to assess patient safety throughout the trial.

The trial was funded by the UK National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) Efficacy and Mechanism Evaluation programme (11/30/07).

The trial was sponsored by Hull University Teaching Hospitals NHS Trust.

The trial was adopted by the Comprehensive Clinical Research Network (CCRN) and the Comprehensive Local Research Networks (CLRNs).

The protocol is available on the trial website and as a supplement linked to the New England Journal of Medicine publication.[65] www.birmingham.ac.uk/stopacei **(last accessed 9th November 2022)**.

Participants

Adults (≥ 18 years) with CKD stage 4 or stage 5 [eGFR < 30 ml/minute/1.73 m^2, using the MDRD equation (MDRD$_{175}$)], who were not receiving dialysis and who had not received a kidney transplant were eligible for participation provided the eGFR had declined by at least 2 ml/minute/1.73 m^2 per year over the previous 2 years and they were receiving treatment with either an ACEi or ARB, or combination of both, for more than 6 months. Exclusion criteria included uncontrolled hypertension or a history of myocardial infarction or stroke within the previous 3 months. Full inclusion and exclusion criteria are detailed below. All participants provided written informed consent.

Inclusion criteria

- Aged ≥ 18 years (male or female).
- CKD stage 4 or stage 5 (eGFR < 30 ml/minute/1.73 m^2 using the MDRD equation) and must not have received a kidney transplant or be on dialysis therapy.

- Progressive deterioration in kidney function (fall in eGFR of ≥ 2 ml/minute/year over previous 24 months) as measured by linear regression analysis [There was a requirement of a minimum of three measurements of eGFR to identify a > 2 ml/minute fall over 1 year to enter the trial. The loss in eGFR was expressed 'per year' so that over 12 months there must have been loss of 2 ml/minute or more, but over 24 months there must have been a total loss of 4 ml/minute or more. The last eGFR was within 3 months of randomisation. We recognise the limitations of eGFR due to intra- and interpatient variability in serum creatinine. Based on a reported intraindividual variation for serum creatinine of 4.3% and intralaboratory variation of 3.0%, a variation of 13% can be considered 'real' with 95% probability. The power function in the MDRD equation has a component of variability that increases the threshold for potential variation between two tests to 14.4%. Hence, a minimum of three eGFRs over 1 year or 6 over 2 years would be required to accurately identify a decline of ≥ 2 ml/minute/year in people with an eGFR < 30 ml/minute/1.73 m2. This optimised the eGFR slope against time. The eGFR slope was calculated using an Excel spreadsheet which allowed entry of the previous creatinine measurements or eGFR values with automatic generation of a slope and rate of GFR loss. This program was provided to all principal investigators (PIs) for centres participating in the trial. The measurements of eGFR were inserted into the table with the date of the measurements and this generates the linear line with automatic calculation of the change in GFR].
- Treatment with either an ACEi or ARB or a combination of both for > 6 months with at least 25% of the maximum recommended daily dose on the day of consent.
- Resting BP ≤ 160/90 mmHg when measured in accordance with British Hypertension Society guidelines in clinic or recent home BP reading within the previous month or a 24-hour ambulatory BP measurement within the last 3 months were acceptable.
- At least 3 months of specialist kidney follow-up at the time of entry into the trial.
- Written, signed informed consent to the trial.

Exclusion criteria

- Aged < 18 years.
- Uncontrolled hypertension (> 160/90 mmHg) or requirement for five or more agents to control BP.
- Undergoing dialysis therapy.
- Previous kidney transplant (functional).
- Any condition which, in the opinion of the investigator, makes the participant unsuitable for trial entry due to prognosis/terminal illness with a projected survival of < 12 months.
- History of myocardial infarction or stroke in preceding 3 months.
- Participation in an interventional research study in preceding 6 weeks.
- Pregnancy confirmed by positive pregnancy test or breastfeeding.
- Inability to provide informed consent (e.g. due to cognitive impairment).
- Immune mediated kidney disease requiring disease specific treatment.
- Known drug or alcohol abuse.
- Inability to comply with the trial schedule and follow-up.

Screening and eligibility

Eligibility was assessed against the inclusion and exclusion criteria and participants were then identified as described below.

Patients with CKD under the care of a nephrologist were reviewed regularly (e.g. every 3 months) in a hospital outpatient clinic. Potential participants in secondary care were identified by the research team at each of the recruiting centres (e.g. from medical records, clinical records, individual kidney unit databases or other local registries) and were invited to participate by letter. In some cases, the research nurse or responsible clinician for the potential participant introduced the study before providing the invitation letter and participant information sheet (PIS).

Members of the site staff screened for potential eligible trial participants using the inclusion/exclusion criteria. Patients who fulfilled the inclusion criteria had their eligibility assessed by medically qualified personnel with access to and a full understanding of their medical history.

Informed consent procedure

Potential participants were initially provided with a PIS (i.e. the current Main Research Ethics Committee (MREC) approved version on appropriately headed paper) and a covering letter explaining the trial to them and inviting them to participate in the trial. This was sent to them before their next clinic attendance. They had time to consider the trial and decide whether they wished to take part, and to discuss the trial with their family and friends. At their next clinic appointment, potential participants had plenty of time to discuss the trial further and to have any questions that they may have about the trial answered. The nature and requirements of the trial were carefully explained. This individual discussed the trial with them in detail and gave a comprehensive verbal explanation of the trial (explaining both the investigational and standard treatment options and highlighting any possible benefits or risks relating to participation). The investigator, or designated medically qualified personnel, explained that there was no obligation for a potential participant to enter the trial, that trial entry was entirely voluntary, and that it was up to the potential participant to decide whether or not they would like to join. It was explained that the potential participant could withdraw at any time during the trial, without having to give a reason and that their decision would not affect the standard of care they received. Throughout the study, participants were encouraged to ask questions and were reminded that they could withdraw at any time without their clinical care being affected. Any reasons for non-participation were recorded if the information was volunteered.

At the appointment (baseline assessment), the research nurse went through the randomisation form including the eligibility checklist. The participant and responsible clinician signed the informed consent form, and the responsible clinician performed a final confirmation of eligibility.

Randomisation procedures

After all eligibility criteria had been confirmed and informed consent had been received, the participants were randomised into the STOP-ACEi trial. Participants were randomised individually into the trial in a one to one ratio to either continue with their RAS inhibitors treatment or discontinue their ACEi and/or ARB treatment.

Randomisation and blinding

Patients were randomly assigned using a centralised internet-based system hosted at BCTU in a 1 : 1 ratio to either discontinue or continue RAS inhibitors. Minimisation was used to ensure balance between groups for the following variables: age (< 65 or ≥ 65 years), eGFR (< 15 ml/minute/1.73 m^2 or ≥ 15 ml/minute/1.73 m^2), diabetes (type I diabetes, type II diabetes or no diabetes), mean arterial pressure {MAP measured as [(2 × diastolic) + systolic]/3; < 100 or ≥ 100 mm Hg}, and proteinuria [protein-to-creatinine ratio (PCR) < 100 or ≥ 100 mg/mmol].

Telephone and online randomisation

Participants could be randomised into the trial via a secure 24-hour internet-based registered service (www.trials.bham.ac.uk/stopacei) or by a telephone call (telephone number 0800 953 0274) to the BCTU. Telephone randomisation was available Monday–Friday, 09:00–17:00. For the secure internet

randomisation, each site and each researcher were provided with a unique log-in username and password in order to access the online system. Online randomisation was available 24 hours a day, 7 days a week, apart from short periods of scheduled maintenance and occasional network problems.

Randomisation Notepads were provided to investigators and were completed and used to collate the necessary information prior to randomisation. All questions and data items on the Randomisation Notepad were answered before a Trial Number could be given. If data items were missing, randomisation was suspended, but could be resumed once the information was available. Only when all eligibility criteria and baseline data items had been provided was a Trial Number allocated.

With the participant's prior consent, their general practitioner (GP) was informed.

Back-up randomisation

If the internet-based randomisation service was unavailable for an extended period of time, a back-up paper randomisation was also available at the BCTU. The randomisation list was produced using a random-length block design. In this instance, investigators rang the BCTU randomisation service (telephone number 0800 953 0274). This was not required during the trial.

Follow-up
Patients were followed-up every 3 months from randomisation to 3 years with a 3-month window for visits.

Intervention

Trial treatment
For those randomised to discontinuing RAS inhibitors, any guideline-recommended antihypertensive agent other than RAS inhibitors could be used to control BP.[66] Re-initiation of RAS inhibitors was permitted only as a last resort when other agents had failed or were not tolerated. For those randomised to continue RAS inhibitors, the investigator chose the agent and dose and could combine it with any other guideline-recommended antihypertensive agent to control BP.[66] In both groups, BP was controlled to target (≤ 140/85 mmHg) and monitored as recommended by UK National Institute for Health and Care Excellence (NICE) Hypertension and CKD guidelines.[63,66]

Stop group

These participants discontinued RAS inhibitors treatment from the point of randomisation onwards. If a participant was due to take an RAS inhibitor on the morning of the randomisation visit (i.e. before randomisation), this was taken as normal. To compensate for the loss of antihypertensive activity, additional antihypertensive treatment was allowed to be commenced. Any antihypertensives used in routine clinical practice were permitted to control BP throughout trial participation, but excluding ACEi or ARBs, except as a last resort. Any of the following alternative antihypertensives could be prescribed: calcium channel blockers, alpha- and beta-adrenoreceptor antagonists, hydralazine, minoxidil and thiazides or those deemed by the responsible clinician. It was acceptable to use aldosterone receptor antagonists (e.g. spironolactone) in the discontinue arm. The normal contraindications and safety precautions for use of these treatments were adhered to, as per routine care. We recommended that the Renal Pharmacy Handbook was consulted in combination with the British National Formulary due to the complex prescribing needs of patients with CKD. In all cases, it was considered best to commence treatment at low doses and then increase to a therapeutic level. The choice of antihypertensive depended on the other treatments being taken by the participant and was at the discretion of the responsible clinician.

Continue group

These participants continued on 'standard' care and continued their RAS inhibitor treatment. The choice and dose of RAS inhibitors were at the discretion of the responsible clinician.

Both treatment groups

In both groups, BP was controlled in participants in the trial to the target BP outlined by the NICE Hypertension guideline (clinical guideline number 127) and NICE CKD guideline (clinical guideline number 73).[63,66] The standard BP target was used (≤ 140/85 mmHg). Currently it remains unknown if there is an optimal BP for delaying kidney progression and it is not clear whether there is any advantage to hypertension control using RAS inhibitors for BP reduction. RAS inhibitors could be used if the clinical status of the participant required this at any time in the trial and was closely monitored, with the potential for the Data Monitoring and Ethics Committee (DMEC) to close the trial should there be significant dilution of the trial groups. All participants remained in the study, irrespective of inability to control BP, as this could occur in normal clinical practice, but all efforts were made to optimise BP and any treatment given were recorded at the follow-up visit.

The monitoring of BP was consistent with the NICE CKD guideline.[66] As detailed home readings and 24-hour ambulatory BP readings were acceptable for the trial at baseline. Home readings or clinic BP readings were also acceptable at follow-up visits.

Between the 3-monthly visits, patients were monitored and managed in accordance with local practice for follow-up of any change of therapy. Any changes in medication or visits to a GP practice or hospital reported by the participant were recorded in the source data and reported on the case report form (CRF) for the next clinic visit.

Measurement of angiotensin-converting enzyme (ACE) and renin levels at baseline and at 1, 2 and 3 years were carried out as a measure of adherence in a selection of patients. It is recognised, however, that when a RAS inhibitor is discontinued the normal biological effect is a reduction in renin and angiotensin I and an increase in ACE activity but these effects only last up to 2 weeks and then return to basal levels.

Throughout the trial, investigators/responsible clinicians prescribed any concomitant medications or treatments deemed necessary to provide adequate supportive care to participants. Medication changes were recorded in the source data at each follow-up visit and reported in the CRF. In addition, the dose of ESA prescribed was recorded in the source data and reported in the CRF.

Adherence

We attempted to minimise the loss to follow-up in this study by (1) emphasising to participants the importance of their attendance at follow-up assessments even if they were no longer compliant with the intervention, (2) reducing outcome assessment appointments during the coronavirus pandemic (COVID-19), (3) using a reminder protocol with telephone contact and (4) providing travel remuneration (including, where necessary, taxi costs).

Data for adherence were collected at each follow-up visit to ensure that adherence was measured for each patient at each study time point up to needing dialysis or receiving a kidney transplant. When we were developing the statistical analysis plan, we considered incorporating a per-protocol analysis into the statistical protocol. However, since adherence was measured at each time point, it is therefore possible that participants were adherent at one visit, non-adherent at the following visit and then adherent again at later visits. Consequently, there was no straightforward way to compute an overall adherence measure for per-protocol analysis. We also discussed this with the data monitoring committee, and they agreed that it was best to just describe the level of adherence at each time point.

It was noted that considering the length of follow-up and that the trial was open-label, the levels of adherence are in line with expectations when compared with large blinded CV trials which report 20–30% treatment non-compliance over shorter duration. Treatment non-compliance was commonly due to worsening renal function in the continue arm but, interestingly, this was also reported as a reason in the stop arm.

Outcomes

Primary outcome
The primary outcome was kidney function at 3 years as calculated according to the $MDRD_{175}$ four-variable eGFR.[67] Data for the primary outcome were censored at the initiation of KRT (dialysis or transplantation).

Secondary outcome measures
Secondary outcome measures included time until the development of ESKD (as defined by the local investigator according to criteria that included terminal palliative care or KRT); a composite of a decrease of more than 50% in the eGFR, the development of ESKD, or the initiation of KRT; hospitalisation for any cause; quality of life (as measured on the KDQoL 36-Item Short Form Survey, version 1.3); exercise capacity (as assessed by the 6-minute walk test); measures of cystatin C and BP; and CV events and death. At the time of this report, the transfer and processing of samples for cystatin C measurement had not yet occurred, so the results are not provided here. Secondary mechanistic outcomes included measures of haemoglobin and urinary protein excretion (PCR) and ESA requirements.

Quality of life

KDQoL-SF 1.3 is a disease-specific quality of life measure. The KDQoL-SF 1.3 questionnaire includes the 36-item Short Form Health Survey (SF-36) as generic core plus symptoms/problems of kidney disease scales.

Safety and monitoring of the intervention
All adverse and serious AEs were recorded.

Statistical considerations

Sample size calculation
Limited data were available upon which to calculate the sample size for the STOP-ACEi trial. One observational study by Ahmed *et al.*[13] provided data on eGFR in 52 patients with advanced CKD in the 12 months prior to stopping RAS inhibitor treatment, at the point of stopping RAS inhibitors and 12 months after stopping (see below). These data were used for the basis of the sample size calculation.

To detect a minimum relevant difference (MRD) in eGFR between groups of 5 ml/minute/1.73 m^2 (i.e. an effect size of 0.31, assuming a SD of 16 ml/minute/1.73 m^2) with 80% power and alpha = 0.05, required 410 participants (205 per group) including a 20% attrition rate.

Mean ± Std. error (SD)	12 months before RAS inhibitors were discontinued	When RAS inhibitors were discontinued	12 months after RAS inhibitors were discontinued
eGFR (ml/minute/1.73 m^2)	22.9 ± 1.4 (10.1)	16.38 ± 1 (7.2)	26.6 ± 2.2 (15.9)

To err on the side of caution, the largest SD above was used to estimate the variability for the eGFR (i.e. a SD of 16 ml/minute/1.73 m^2) for the sample size calculation.

Statistical analysis

Statistical analyses were based on the intention-to-treat (ITT) principle and were adjusted for the minimisation variables and baseline values (where available). The ITT population included all randomised participants, with participants analysed according to the group to which they were randomised, regardless of what treatment (if any) they received. All available data for participants that were lost to follow-up or withdrew, or had died prior to completing the final trial follow-up, were included in the analysis. The reference group for all analyses was those who continued RAS inhibitors. The statistical analysis plan did not provide correction for multiplicity; therefore secondary outcomes are reported as point estimates and 95% CIs. Analyses were performed with SAS software version 9.4 (SAS Institute) and Stata software version 17 (Stata-Corp).

Full details of the analysis methods are provided in the Statistical Analysis Plan (Supplementary Appendix available with the *New England Journal of Medicine* paper).[65] The primary outcome was analysed using a repeated-measures, mixed-effects linear regression model (which included a time-by-treatment-group interaction term) to estimate the difference between groups in eGFR at 3 years. A compound symmetry covariance structure was assumed. Any measurements of eGFR made after starting dialysis or receiving a kidney transplant were excluded. To examine the impact of data that were not missing at random, sensitivity analyses (fitting pattern mixture and joint models) were performed for the primary outcome. We also repeated analyses for the primary outcome using the Chronic Kidney Disease Epidemiology Collaboration 2009 (CKD-EPI 2009) and MDRD$_{186}$ four-variable equations for eGFR.

Continuous secondary outcomes, such as BP, were analysed using the same methods as for the primary outcome, but data were not censored when KRT was started. Categorical (dichotomous) secondary outcomes were analysed using a Poisson regression model with robust standard errors (SEs) to estimate the RR and 95% CI, as the log-binomial model failed to converge. Time-to-event outcomes, such as time to ESKD, were analysed using a Cox proportional-hazards model to obtain a HR and 95% CI. Categorical (dichotomous) safety outcome measures [hospitalisations, serious adverse events (SAEs)] were summarised as the proportion of participants and percentages and compared using a chi-squared test.

Data collection for kidney outcomes did not distinguish between ESKD and KRT outcomes (i.e. they were coded the same, apart from the free-text entry).

Subgroup analyses

The minimisation variables in the randomisation process were diabetes [type 1 diabetes, type 2 diabetes (including insulin-treated type 2 diabetes), no diabetes], BP {MAP measured as [(2 × diastolic) + systolic]/3; < 100 or ≥ 100}, age (< 65 or ≥ 65 years), proteinuria (PCR < 100 or ≥ 100 mg/mmol), and eGFR measurement (< 15 or ≥ 15 ml/minute/1.73 m^2).

Several a priori subgroup analyses were planned with respect to the above minimisation variables for the primary outcome. The analysis methods followed those of the primary outcome. To allow for the possibility of differential changes over time within subgroups, time by subgroup and the three-way interaction between treatment, time and subgroup were included in the model. Although all data were included in the regression models for the subgroup analyses, estimates of differences are only presented at 3 years. Given the well-known dangers of subgroup analyses, these analyses were treated as hypothesis-generating.

Safety analyses

Discontinuations from the intervention and permanent study withdrawals and their reasons were tabulated. Adherence was assessed where possible from the CRFs. The chief investigator reviewed all AEs submitted by PIs except those from their own unit. These were reviewed by another primary investigator on the TMG.

Cardiovascular event data (as part of the safety data) are summarised using descriptive statistics. The total number of patients with at least one event for each event type (i.e. heart failure, stroke, myocardial infarction) and total number of events for each event type is tabulated by treatment arm and overall.

Data monitoring and quality assurance

The trial was co-ordinated by a TMG, consisting of the chief investigator, Trials Management Team Leader and Senior Trial Manager and the senior and trial statistician. The Trial Manager co-ordinated the study and was accountable to the chief investigator. The Trial Office was responsible for randomisation, collection of data in collaboration with the research co-ordinator, data processing and analysis. A TSC was established to oversee the conduct and progress of the trial. The study's funder, NIHR HTA formally appointed the chair and members after the nominations from the TMG. A charter was drawn up to describe membership, roles and responsibilities of the TSC. The Independent DMEC was an independent group of experts, consisting of a nephrologist, a lay member and a statistician, who monitored patient safety and treatment efficacy data while the clinical trial was ongoing; the primary mandate of this committee was to protect patient safety.

Chapter 3　Patient and public involvement

Patient and public involvement input into original intervention development

The planning and delivery of the STOP ACEi trial were facilitated by close engagement with people living with CKD and on RAS inhibition therapy. Patients contributed directly to both the development of trial materials [e.g. patient information leaflets (PILs) and consent forms] and the way the trial was conducted.

Two groups have been involved in the study design:

1. a focus group
2. a kidney user group.

At an early stage, the team co-developed the project with the assistance of a focus group. The focus group included patients, nurses and service users and was funded by a Yorkshire Public Patient Involvement (PPI) grant. They have met on four occasions to discuss trial design and assisted in the final development of the information leaflets to ensure they were appropriate and acceptable.

A renal user patient group, some of whom met the criteria for the trial, was gathered together during the running of the trial to assist in recommending ideas to promote recruitment to the trial and provide any observations or comments on the trial. The chief investigator regularly spoke with patients on their experience of the trial and advice on any further suggestions. He ensured that patients were content with the burden of baseline and 3-monthly follow-up assessments were acceptable to also. This feedback was extremely useful and was reassuring that patients were fully informed about the commitment required for the research and understood the main aspects of trial design.

Patient and public involvement input to the Trial Steering Committee

During the running of the trial a patient representative has served on the TSC. This was a patient with kidney disease. As a TSC member they played a vital part in project oversight and management of the trial and made recommendations that were taken forward to improve the running and conduct of the trial. They contributed to all the meetings they were able to attend and provided valuable input.

The results of the trial will be fed back to all patients in the kidney community via the investigators.

Chapter 4 Results

Recruitment

Between 11 July 2014 and 19 June 2018, 17,290 patients were screened at 39 participating centres in the UK and 1210 patients were invited to participate in the trial (see *Figure 1*), with 411 patients at 37 centres randomised into the trial; 206 to discontinue and 205 to continue RAS inhibitors. Follow-up continued until 19 June 2021. The median follow-up was 3 years [mean (SD) 2.7 (0.8) years].

FIGURE 1 CONSORT diagram.
Details are shown regarding the screening, potential eligibility, randomised assignments and disposition of the trial patients. Among the patients who died during the trial, three had completed the 3-year assessment before death, so their data were included in the analysis. This factor explains the difference in the total number of deaths that were reported in the trial. ACE denotes angiotensin-converting enzyme, and RAS denotes renin–angiotensin system.

Demographic and baseline characteristics

Patient characteristics at baseline are shown in *Tables 1–3*. Median age was 63 years, 281 (68.4%) were men and 60 (14.6%) were non-white. The median eGFR was 18 ml/minute/1.73 m^2; 118 (28.7%) had an eGFR of < 15 ml/minute/1.73 m^2. The median level of proteinuria (PCR) was 115 mg/mmol (interquartile range 28–248 mg/mmol) and the median haemoglobin was 116 g/l (interquartile range, 107–125). Diabetes (either type 1 or type 2) had been diagnosed in 153 patients (37%), diabetic nephropathy in 87 patients (21%), hypertensive/renovascular nephropathy in 68; (17%), genetic diseases in 81 (20%), and glomerulonephritis in 76 (18%) to account for most cases of CKD (see *Table 3*).

TABLE 1 Baseline characteristic data for STOP and continue groups

Baseline characteristics	STOP (*N* = 206)	Continue (*N* = 205)	Total (*N* = 411)
Age (years)			
N	206	205	411
Mean (SD)	62.7 (12.6)	61.4 (13.6)	62.1 (13.1)
Median (IQR)	63.3 (54.4–73.1)	63.3 (50–71.6)	63.3 (51.4–72.1)
Minimum–maximum	28.8–90.6	28.3–85.8	28.3–90.6
Age group[a]			
< 65 years	116 (56.3%)	110 (53.7%)	226 (55%)
≥ 65 years	90 (43.7%)	95 (46.3%)	185 (45%)
Gender			
Male	140 (68%)	141 (68.8%)	281 (68.4%)
Female	66 (32%)	64 (31.2%)	130 (31.6%)
BMI			
N	205	202	407
Mean (SD)	29.9 (5.9)	29.7 (6.4)	29.8 (6.2)
Median (IQR)	29.4 (25.4–33.6)	29 (25.5–32.5)	29.3 (25.5–33.2)
Minimum–maximum	16.6–49.3	16–60.6	16–60.6
Haemoglobin (Hb) (g/l)			
N	205	202	407
Mean (SD)	117 (15)	117 (14)	117 (15)
Median (IQR)	116 (108–127)	116 (107–124)	116 (107–125)
Minimum–maximum	58–161	87–169	58–169
Serum creatinine (micromole/l)			
N	206	203	409
Mean (SD)	321.2 (107.8)	314.6 (97.9)	317.9 (102.9)
Median (IQR)	299.5 (242–372)	298 (243–367)	299 (243–367)
Minimum–maximum	152–796	140–690	140–796

TABLE 1 Baseline characteristic data for STOP and continue groups (*continued*)

Baseline characteristics	STOP (*N* = 206)	Continue (*N* = 205)	Total (*N* = 411)
eGFR (ml/minute/1.73 m²)			
N	206	205	411
Mean (SD)	17.7 (5.4)	17.9 (5)	17.8 (5.2)
Median (IQR)	18 (14–22)	18 (14–21)	18 (14–22)
Minimum–maximum	6–30	7–30	6–30
eGFR group[a]			
< 15 ml/minute	58 (28.2%)	60 (29.3%)	118 (28.7%)
≥ 15 ml/minute	148 (71.8%)	145 (70.7%)	293 (71.3%)
Rate of decline eGFR (ml/minute/1.73 m²)			
N	206	205	411
Mean (SD)	−6.0 (4)	−6.3 (4.7)	−6.2 (4.3)

BMI, body mass index; IQR, interquartile range.
a Minimisation variables.

TABLE 2 Additional baseline characteristic data for STOP and continue groups and total

Baseline characteristics	STOP (*N* = 206)	Continue (*N* = 205)	Total (*N* = 411)
Albumin (g/l)			
N	205	202	407
Mean (SD)	39.9 (5)	40.1 (4.1)	40 (4.6)
Median (IQR)	40 (37–43)	40 (38–43)	40 (37–43)
Minimum–maximum	26–50	26–50	26–50
C-Reactive protein (CRP), (mg/l)			
N	187	184	371
Mean (SD)	6.4 (7.6)	7.2 (9.8)	6.8 (8.8)
Median (IQR)	4 (2–7)	4.9 (2–7.6)	4.6 (2–7)
Minimum–maximum	0–47	0–74	0–74
Bicarbonate (mmol/l)			
N	198	194	392
Mean (SD)	22.3 (3.4)	22.2 (2.9)	22.3 (3.2)
Median (IQR)	22 (20–24)	22 (20–24)	22 (20–24)
Minimum–maximum	13–32	14–31	13–32
Potassium (mmol/l)			
N	206	202	408
Mean (SD)	4.9 (0.6)	5 (0.6)	5 (0.6)

TABLE 2 Additional baseline characteristic data for STOP and continue groups and total (*continued*)

Baseline characteristics	STOP (*N* = 206)	Continue (*N* = 205)	Total (*N* = 411)
Median (IQR)	5 (4.6–5.4)	5 (4.6–5.4)	5 (4.6–5.4)
Minimum–maximum	2.9–6.3	3.3–6.6	2.9–6.6
Proteinuria (mg/mmol)			
N	206	205	411
Mean (SD)	178.6 (209.3)	172.8 (198.9)	175.7 (203.9)
Median (IQR)	108.5 (26–236)	117 (30–252)	115.2 (28–248)
Minimum–maximum	0.3–1209	1–1137	0.3–1209
Proteinuria group[a]			
< 100	97 (47.1%)	98 (47.8%)	195 (47.4%)
≥ 100	109 (52.9%)	107 (52.2%)	216 (52.6%)
Systolic BP (mmHg)			
N	206	205	411
Mean (SD)	136.5 (12.9)	136.3 (13.7)	136.4 (13.3)
Median (IQR)	136 (129–147)	138 (126–147)	137 (128–147)
Minimum–maximum	99–160	98–160	98–160
Diastolic BP (mmHg)			
N	206	205	411
Mean (SD)	75.7 (9.2)	76 (8.9)	75.9 (9.1)
Median (IQR)	77 (70–82)	77 (70–82)	77 (70–82)
Minimum–maximum	40–90	45–90	40–90
MAP			
N	206	205	411
Mean (SD)	96 (8)	96.1 (8.5)	96 (8.3)
Median (IQR)	97.3 (91.7–102.7)	97 (90.7–101.7)	97 (91–102)
Minimum–maximum	71.3–113.3	70.7–112.7	70.7–113.3
MAP group[a]			
< 100	132 (64.1%)	129 (62.9%)	261 (63.5%)
≥ 100	74 (35.9%)	76 (37.1%)	150 (36.5%)
Alcohol intake (units)			
None	88 (42.7%)	94 (45.9%)	182 (44.3%)
≤ 20 per week	103 (50%)	96 (46.8%)	199 (48.4%)
> 20 per week	13 (6.3%)	12 (5.9%)	25 (6.1%)
Missing	2 (1%)	3 (1.5%)	5 (1.2%)
Smoking status			
Never smoker	86 (41.7%)	100 (48.8%)	186 (45.3%)
Ex-smoker	97 (47.1%)	80 (39%)	177 (43.1%)

TABLE 2 Additional baseline characteristic data for STOP and continue groups and total (*continued*)

Baseline characteristics	STOP (*N* = 206)	Continue (*N* = 205)	Total (*N* = 411)
Current smoker	23 (11.2%)	23 (11.2%)	46 (11.2%)
Missing	0 (0%)	2 (1%)	2 (0.5%)
Diabetes[a]			
Type 1	9 (4.4%)	11 (5.4%)	20 (4.9%)
Type 2	66 (32%)	67 (32.7%)	133 (32.4%)
No diabetes	131 (63.6%)	127 (62%)	258 (62.8%)

IQR, interquartile range.
a Minimisation variables.

TABLE 3 Baseline characteristic data of ethnicity for STOP and continue groups and total

Baseline characteristics	STOP (*N* = 206)	Continue (*N* = 205)	Total (*N* = 411)
Ethnicity			
White – English/Welsh/Scottish/Northern Irish/British	168 (81.6%)	168 (82%)	336 (81.8%)
White – Irish	3 (1.5%)	4 (2%)	7 (1.7%)
White – any other white background	0 (0%)	8 (3.9%)	8 (1.9%)
Mixed/multiple ethnic group - white and black Caribbean	1 (0.5%)	1 (0.5%)	2 (0.5%)
Mixed/multiple ethnic group – white and black African	1 (0.5%)	0 (0%)	1 (0.2%)
Mixed/multiple ethnic group – any other mixed/multiple ethnic background	1 (0.5%)	1 (0.5%)	2 (0.5%)
Asian/Asian British – Indian	5 (2.4%)	8 (3.9%)	13 (3.2%)
Asian/ Asian British – Pakistani	5 (2.4%)	3 (1.5%)	8 (1.9%)
Asian/Asian British – Bangladeshi	0 (0%)	1 (0.5%)	1 (0.2%)
Asian/Asian British – Chinese	2 (1%)	1 (0.5%)	3 (0.7%)
Asian/Asian British – any other Asian background	2 (1%)	3 (1.5%)	5 (1.2%)
Black/African/Caribbean/black British – African	8 (3.9%)	3 (1.5%)	11 (2.7%)
Black/African/Caribbean/black British – Caribbean	5 (2.4%)	4 (2%)	9 (2.2%)
Black/African/Caribbean/black British – other	3 (1.5%)	0 (0%)	3 (0.7%)
Any other	2 (1%)	0 (0%)	2 (0.5%)

Prior cardiovascular events and risk factors

Clinically overt CV disease was not common in the participant population recruited to the trial (see *Table 4*). The prevalence of CV disease (a history of one or more of the following: myocardial infarction 9%, stroke 6%, heart failure hospitalisation 2%, atrial fibrillation 4%, or peripheral vascular disease 5%) varied, but was overall low at baseline. Just under half of the participants (45.3%) had never smoked, and 71% had hypertension at baseline.

Most participants (58%) were on three or more antihypertensive medicines; 268 (65.5%) were on a statin (see *Tables 5* and *6*). Forty per cent (163/411) were on oral bicarbonate supplements. The use of SGLT2 inhibitors was very low at < 1% and no patients were documented to be taking a potassium binder. Approximately 20% of participants were taking ESA therapy.

Adherence to treatment

In the first 3 months, 180 (94.2%) participants who were randomised to stop RAS inhibitors were reported as being adherent compared with 179 (94.2%) participants who were randomised to continue RAS inhibitors. At 36 months of those who had not withdrawn from the trial, commenced dialysis, received a kidney transplant or died, 50 of 57 (87.7%) participant randomised to discontinue remained off RAS inhibitors compared with 53 of 69 (76.8%) participants randomised to continue on RAS inhibitors (see *Table 7*).

TABLE 4 Cardiovascular events at baseline

CV events at baseline	STOP (N = 206)	Continue (N = 203)[a]	Total (N = 409)[a]
Ever had a major CV event			
Hospitalisation for heart failure	1 (< 1%)	5 (2%)	6 (1.5%)
Myocardial infarction (ST elevation)	11 (5%)	9 (4%)	20 (5%)
Myocardial infarction (non ST elevation)	8 (4%)	8 (4%)	16 (4%)
Stroke	10 (5%)	16 (8%)	26 (6%)
Heart failure at baseline	7 (3%)	8 (4%)	15 (4%)
Other CV disease or event (previous or current)			
Angina	9 (4%)	17 (8%)	26 (6%)
Coronary intervention (angioplasty)	10 (5%)	12 (6%)	22 (5%)
Coronary intervention (coronary artery bypass)	6 (3%)	8 (4%)	14 (3%)
Carotid intervention	2 (1%)	2 (1%)	4 (1%)
Hypertension	147 (71%)	147 (72%)	294 (72%)
Atrial fibrillation/flutter	9 (4%)	9 (4%)	18 (4%)
Venous thromboembolism	6 (3%)	1 (< 1%)	7 (2%)
Peripheral vascular disease	11 (5%)	10 (5%)	21 (5%)
Other CV condition	20 (10%)	18 (9%)	38 (9%)

a Two participants dropped out from the study before completing the baseline assessment.
Note
Data represented as numbers and (%) for each group and total.

TABLE 5 Antihypertensive medications at baseline

Antihypertensive medications at baseline	STOP (N = 206)	Continue (N = 203)[a]	Total (N = 409)[a]
ACEi/ARB			
ACEi	99 (48%)	123 (61%)	222 (54%)
ARB	104 (51%)	77 (38%)	181 (44%)
Both ACEi and ARB	3 (1%)	3 (1%)	6 (2%)
Calcium channel blocker	137 (66%)	132 (65%)	269 (66%)
Loop diuretic	67 (33%)	66 (33%)	133 (33%)
Thiazide diuretic	11 (5%)	13 (6%)	24 (6%)
Thiazide-like diuretic	4 (2%)	9 (4%)	13 (3%)
Potassium-sparing diuretic	1 (< 1%)	2 (1%)	3 (1%)
Mineralocorticoid receptor agonist	2 (1%)	0 (0%)	2 (< 1%)
Alpha-blocker	65 (32%)	66 (33%)	131 (32%)
Beta-blocker	63 (31%)	69 (34%)	132 (32%)
Methyldopa	0 (0%)	1 (< 1%)	1 (< 1%)
Moxonidine	2 (1%)	6 (3%)	8 (2%)
Hydralazine	0 (0%)	1 (< 1%)	1 (< 1%)
Other antihypertensive	4 (2%)	3 (1%)	7 (2%)
Number of antihypertensives taken by participant at baseline			
Mean (SD)	2.7 (1.2)	2.8 (1.2)	2.8 (1.2)
Median (IQR)	3 (2–4)	3 (2–4)	3 (2–4)
Minimum–maximum	1–6	1–7	1–7

IQR, interquartile range.
a Two participants dropped out from the study before completing the baseline assessment.
Note
Data represented as numbers and (%) for each group and total.

TABLE 6 Other concomitant medications at baseline

Other concomitant medications at baseline[a]	STOP (N = 206)	Continue (N = 203)[b]	Total (N = 409)[b]
Statin	134 (65%)	134 (66%)	268 (65.5%)
Fibrate	4 (1.9%)	5 (2.5%)	9 (2.2%)
Ezetimibe	13 (6.3%)	7 (3.4%)	20 (4.9%)
Digoxin	1 (0.5%)	3 (1.5%)	4 (1%)
Nitrate	5 (2.4%)	10 (4.9%)	15 (3.7%)
Aspirin	65 (31.6%)	62 (30.5%)	127 (31.1%)
Clopidogrel	12 (5.8%)	9 (4.4%)	21 (5.1%)
Warfarin	8 (3.9%)	12 (5.9%)	20 (4.9%)

TABLE 6 Other concomitant medications at baseline *(continued)*

Other concomitant medications at baseline[a]	STOP (*N* = 206)	Continue (*N* = 203)[b]	Total (*N* = 409)[b]
GLP-1 analogues/agonists	3 (1.5%)	1 (0.5%)	4 (1%)
Metformin	1 (0.5%)	1 (0.5%)	2 (0.5%)
Sodium glucose transporter 2 inhibitor	1 (0.5%)	1 (0.5%)	2 (0.5%)
Thiazolidinedione/glitazone	1 (0.5%)	3 (1.5%)	4 (1%)
DPP-4 inhibitor	16 (7.8%)	22 (10.8%)	38 (9.3%)
Sulphonylurea	17 (8.3%)	13 (6.4%)	30 (7.3%)
Bicarbonate	75 (36.4%)	88 (43.3%)	163 (39.9%)
Bisphosphonate	1 (0.5%)	4 (2%)	5 (1.2%)
Phosphate binders	15 (7.3%)	15 (7.4%)	30 (7.3%)
Calcium/vitamin D	103 (50%)	101 (49.8%)	204 (49.9%)
Prednisolone	4 (1.9%)	5 (2.5%)	9 (2.2%)
Mycophenolate mofetil	1 (0.5%)	1 (0.5%)	2 (0.5%)
Ciclosporin	1 (0.5%)	0 (0%)	1 (0.2%)
Cyclophosphamide	1 (0.5%)	0 (0%)	1 (0.2%)
Azathioprine	2 (1%)	1 (0.5%)	3 (0.7%)
Tacrolimus	1 (0.5%)	1 (0.5%)	2 (0.5%)
Methotrexate	1 (0.5%)	0 (0%)	1 (0.2%)
Non-steroidal anti-inflammatory drugs	3 (1.5%)	1 (0.5%)	4 (1%)
N (%) on ESA treatment	38 (18.5%)	43 (21.2%)	81 (19.8%)

DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1.
a Not mutually exclusive, participants can be on more than one other concomitant medication.
b Two participants dropped out from the study before completing the baseline assessment.

TABLE 7 Adherence up to the point of transplantation or dialysis at each 3-month follow-up

Time point (months)	Adherence	STOP	Continue	Total
3	*N* of participants completed follow-up	191	190	381
	Non-adherent	11 (5.8%)	11 (5.8%)	22 (5.8%)
	Adherent	180 (94.2%)	179 (94.2%)	359 (94.2%)
6	*N* of participants completed follow-up	169	177	346
	Non-adherent	16 (9.5%)	19 (10.7%)	35 (10.1%)
	Adherent	153 (90.5%)	158 (89.3%)	311 (89.9%)
9	*N* of participants completed follow-up	151	161	312
	Non-adherent	14 (9.3%)	18 (11.2%)	32 (10.3%)
	Adherent	137 (90.7%)	143 (88.8%)	280 (89.7%)
12	*N* of participants completed follow-up	133	148	281
	Non-adherent	15 (11.3%)	22 (14.9%)	37 (13.2%)
	Adherent	118 (88.7%)	126 (85.1%)	244 (86.8%)

TABLE 7 Adherence up to the point of transplantation or dialysis at each 3-month follow-up (*continued*)

Time point (months)	Adherence	STOP	Continue	Total
15	*N* of participants completed follow-up	117	126	243
	Non-adherent	12 (10.3%)	15 (11.9%)	27 (11.1%)
	Adherent	105 (89.7%)	111 (88.1%)	216 (88.9%)
18	*N* of participants completed follow-up	103	113	216
	Non-adherent	11 (10.7%)	16 (14.2%)	27 (12.5%)
	Adherent	92 (89.3%)	97 (85.8%)	189 (87.5%)
21	*N* of participants completed follow-up	99	102	201
	Non-adherent	10 (10.1%)	14 (13.7%)	24 (11.9%)
	Adherent	89 (89.9%)	88 (86.3%)	177 (88.1%)
24	*N* of participants completed follow-up	89	99	188
	Non-adherent	11 (12.4%)	16 (16.2%)	27 (14.4%)
	Adherent	78 (87.6%)	83 (83.8%)	161 (85.6%)
27	*N* of participants completed follow-up	80	90	170
	Non-adherent	9 (11.3%)	13 (14.4%)	22 (12.9%)
	Adherent	71 (88.8%)	77 (85.6%)	148 (87.1%)
30	*N* of participants completed follow-up	72	85	157
	Non-adherent	8 (11.1%)	19 (22.4%)	27 (17.2%)
	Adherent	64 (88.9%)	66 (77.6%)	130 (82.8%)
33	*N* of participants completed follow-up	61	74	135
	Non-adherent	9 (14.8%)	16 (21.6%)	25 (18.5%)
	Adherent	52 (85.2%)	58 (78.4%)	110 (81.5%)
36	*N* of participants completed follow-up	57	69	126
	Non-adherent	7 (12.3%)	16 (23.2%)	23 (18.3%)
	Adherent	50 (87.7%)	53 (76.8%)	103 (81.7%)

Primary outcome

At 3 years, among the 411 patients who had undergone randomisation, the least-squares mean (LS-Mean) (± SE) eGFR was 12.6 ± 0.7 ml/minute/1.73 m^2 in the discontinuation group and 13.3 ± 0.6 ml/minute/1.73 m^2 in the continuation group [estimated adjusted mean difference: −0.7 ml/minute/1.73 m^2 (95% CI −2.5 to +1.0; p = 0.42); with a negative value indicating the outcome favours continuing RAS inhibitors] (see *Figure 2* and *Table 8*).

There was no evidence that the treatment effect differed when the data were analysed according to the pre-specified subgroups (see *Figure 3*).

Sensitivity analyses using pattern mixture models and a joint model gave similar results, as did the analyses using the two other eGFR equations (CKD-EPI 2009 and the $MDRD_{186}$ four-variable equation) (See *Report Supplementary Material 1*, Tables S1–S4, Figs S1–S17).

FIGURE 2 Primary outcome plot of the LS-Means ± 95% CI over time for revised MDRD$_{175}$ four-variable equation.

TABLE 8 Primary outcome – (MDRD$_{175}$ four-variable)

	Time point (months)	Summary statistic	STOP	Continue
eGFR (ml/minute/1.73 m²)	3	Number of patients with data	N = 187	N = 190
		Empirical mean (SD)	17.1 (6.3)	17.1 (5.8)
		LS-Mean (SE)	18.8 (0.3)	18.8 (0.3
	6	Number of patients with data	N = 166	N = 172
		Empirical mean (SD)	16.5 (6.3)	16.8 (6.6)
		LS-Mean ± (SE)	17.58 ± (0.28)	18.23 ± (0.33)
	9	Number of patients with data	N = 148	N = 157
		Empirical mean (SD)	16.6 (6.3)	16.9 (6.2)
		LS-Mean ± (SE)	16.71 ± (0.31)	17.51 ± (0.31)
	12	Number of patients with data	N = 130	N = 142
		Empirical mean (SD)	16.4 (6.4)	16.7 (6.6)
		LS-Mean ± (SE)	16.12 ± (0.35)	16.72 ± (0.35)
	15	Number of patients with data	N = 117	N = 122
		Empirical mean (SD)	16.3 (6.4)	16.3 (6.3)
		LS-Mean ± (SE)	15.27 ± (0.36)	16.22 ± (0.38)
	18	Number of patients with data	N = 100	N = 108
		Empirical mean (SD)	16.7 (6.8)	17.5 (6.2)
		LS-Mean ± (SE)	14.96 ± (0.43)	16.06 ± (0.40)
	21	Number of patients with data	N = 96	N = 99
		Empirical mean (SD)	16.5 (6.8)	17.2 (6.4)
		LS-Mean ± (SE)	14.49 ± (0.47)	15.67 ± (0.42)

TABLE 8 Primary outcome – (MDRD$_{175}$ four-variable) (*continued*)

	Time point (months)	Summary statistic	STOP	Continue
	24	Number of patients with data	N = 88	N = 95
		Empirical mean (SD)	16.2 (7.4)	16.7 (5.6)
		LS-Mean ± (SE)	13.57 ± (0.54)	14.60 ± (0.39)
	27	Number of patients with data	N = 78	N = 87
		Empirical mean (SD)	16 (7.1)	15.9 (5.6)
		LS-Mean ± (SE)	13.47 ± (0.53)	13.92 ± (0.49)
	30	Number of patients with data	N = 69	N = 80
		Empirical mean (SD)	16.2 (7.4)	16.2 (7)
		LS-Mean ± (SE)	12.84 ± (0.58)	13.88 ± (0.63)
	33	Number of patients with data	N = 59	N = 66
		Empirical mean (SD)	16.1 (7.8)	16.4 (6.5)
		LS-Mean ± (SE)	12.36 ± (0.64)	13.55 ± (0.54)
	36	Number of patients with data	N = 56	N = 69
		Empirical mean (SD)	16.9 (8.1)	16.7 (7)
		LS-Mean ± (SE)	12.56 ± (0.68)	13.28 ± (0.60)

Adjusted for minimisation variables (age, eGFR, proteinuria, MAP, diabetes), time point and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust SEs used. Continue group used as reference category in the model and values > 0 indicate better outcome for patients assigned to discontinuing RAS inhibitor.

Note
Measurements of eGFR made after starting KRT (i.e. dialysis/transplant) are not included in the analysis.

FIGURE 3 Subgroup analysis for the primary outcome at 3 years.

Chapter 5　Secondary outcome analyses of study

Secondary outcomes

Of patients randomised to discontinue RAS inhibitors, 128 (62%) developed ESKD or had KRT (dialysis or transplantation) compared to 115 (56%) randomised to continue RAS inhibitors (adjusted HR 1.28, 95% CI 0.99 to 1.65) (see *Figure 4*).

The number of participants with a > 50% decline in eGFR or starting KRT including ESKD was also similar [140 (68%) if RAS inhibitors were stopped vs. 127 (63%) if RAS inhibitors were continued (adjusted RR 1.07, 95% CI 0.94 to 1.22)] (see *Table 9*).

The number of hospitalisations for any reason (414 vs. 413) and CV events (108 vs. 88) were similar across the two groups (i.e. stop and continue respectively) (see *Table 9*). Twenty patients randomised to discontinue RAS inhibitors and 22 randomised to continue RAS inhibitors died (HR 0.85, 95% CI 0.46 to 1.57) (see *Table 9* and *Figure 5*).

In the first 15 months after randomisation, both systolic and diastolic BP values were higher in those who were randomised to discontinue rather than continue RAS inhibitors. After this point, BP values were similar in the two groups. The difference in LS-Mean at 3 years for systolic BP was 0 mmHg, 95% CI −4 to 5 mmHg. The results were similar for diastolic BP; 0 mmHg, 95% CI −2 to 3 mmHg (see *Figures 6* and *7*). The number of antihypertensive medicines prescribed during the trial was similar between the two groups (see *Table 10*).

At 3 years, the LS-Mean (± SE) distance covered during a 6-minute walk test for those randomised to discontinue RAS inhibitors was 394 ± 19 m compared to 412 ± 9 m in those randomised to continue RAS inhibitors (estimated adjusted mean difference −18, 95% CI −57 to 22) (see *Tables 9* and *11*).

There was no evidence of any meaningful differences between groups in participant quality of life as measured by various domains of KDQoL-SF™ v1.3 (see *Table 12*).

FIGURE 4 Kaplan–Meier curve by treatment group (stop or continue RAS inhibitors) for time to KRT or ESKD.

TABLE 9 Primary outcome, sensitivity analysis and secondary outcomes

Outcomes	STOP RAS inhibitors	Continue RAS inhibitors	Mean difference or RR or HR (95% CI)[a]
Primary outcome – LS-Mean ± (SE) at 3 years			−0.7 (−2.5 to 1.0); $p = 0.42$
eGFR using revised $MDRD_{175}$ four-variable	12.6 ± (0.7)	13.3 ± (0.6)	
Primary outcome sensitivity analysis – LS-Mean ± (SE) at 3 years			
eGFR using CKD-EPI creatinine equation	12.0 ± (0.7)	12.8 ± (0.6)	−0.8 (−2.5 to 1.0)
eGFR using original $MDRD_{186}$ four-variable	13.4 ± (0.7)	14.1 ± (0.6)	−0.8 (−2.6 to 1.1)
Primary outcome sensitivity analysis – pattern mixture models			
eGFR using revised $MDRD_{175}$ four-variable with:			
Flat value five imputation for MNAR eGFR values	-	-	−0.5 (−1.7 to 0.7)
Flat value seven imputation for MNAR eGFR values	-	-	−0.4 (−1.5 to 0.7)
LOCF imputation for MNAR eGFR values	-	-	−0.4 (−1.5 to 0.6)
Primary outcome sensitivity analysis – joint model			
eGFR using revised $MDRD_{175}$ four-variable	-	-	−0.8 (−2.0 to 0.4)
Secondary clinical and safety outcomes			
ESKD or KRT – number with outcome/total number (%)	128/206 (62)	115/205 (56)	1.28 (0.99 to 1.65)
KRT or > 50% decline in eGFR – number with outcome/total number (%)	140/206 (68)	127/202 (63)	1.07 (0.94 to 1.22)
Mortality – number with outcome/total number (%)	20/206 (10)	22/205 (11)	0.85 (0.46 to 1.57)
Number with any hospitalisation – number with outcome/total number (%)	135/206 (66)	147/205 (72)	-
Total hospitalisations – total events	*414*	*413*	-
N with any SAE – number with outcome/total number (%)	107/206 (52)	101/205 (49)	-
Total SAEs – total events	*237*	*253*	-
Total CV events – total events	108	88	-
Systolic BP (mmHg) – LS-Mean ± (SE) at 3 years	140 ± (2)	140 ± (2)	0 (−4 to 5)
Diastolic BP (mmHg) – LS-Mean ± (SE) at 3 years	76 ± (1)	76 ± (1)	0 (−2 to 3)
Distance (in metres) from 6-minute walk test – LS-Mean ± (SE) at 3 years	394 ± (19)	412 ± (9)	−18 (−57 to 22)

TABLE 9 Primary outcome, sensitivity analysis and secondary outcomes (*continued*)

Outcomes	STOP RAS inhibitors	Continue RAS inhibitors	Mean difference or RR or HR (95% CI)[a]
Secondary mechanistic outcomes			
Haemoglobin (g/l) – LS-Mean ± (SE) at 3 years	119 ± (1)	119 ± (1)	0 (−0.3 to 0.4)
uPCR (mg/mmol) – LS-Mean ± (SE) at 3 years	192 ± (31)	193 ± (22)	−1 (−76 to 74)
N with ESA treatment – number with outcome/total number (%)	114/206 (55)	112/202 (55)	0.96 (0.81 to 1.13)

MNAR, missing not at random; LOCF, last observation carried forward.

a All treatment effects are shown as mean difference except for 'ESKD (KRT or terminal palliative care)' and 'Mortality' which is reported as HR, and 'KRT or > 50% decline in eGFR' and 'N with ESA treatment' which is reported as a RR.

Notes

All analyses were adjusted for minimisation variables and baseline value (where available). For any outcomes that were continuous data and collected at multiple time points, time point and treatment by time interaction were also included in the model.

Cardiovascular events which included those reported during safety and included the following (hospitalisation for heart failure, myocardial infarction, stroke, heart failure events, angina, coronary intervention, hypertension, atrial arrhythmias, venous thromboembolism, peripheral vascular disease and other cardiac conditions.

Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

In the secondary clinical analysis, seven patients diagnosed with ESKD did not have KRT and were likely conservative therapy.

Number at risk

Group = continue	205	202	200	197	192	188	184	181	179	177	175	168	119
Group = STOP	206	206	199	197	188	187	181	178	174	170	168	163	113

FIGURE 5 Kaplan–Meier curve by treatment arm for mortality.

Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. The mortality analysis was conducted using time to event analysis. For those patients who did not die, they were censored based on the date of their last follow-up assessment. Some patients in the trial completed the final 3 years' time point slightly earlier than was expected consistent with the protocol visit window of ±6 weeks. Consequently, when computing the actual time (in months) between date of randomisation to the date of last visit, over 90 patients who completed their final 3 years' visit had a computed censoring time in months of slightly < 36 months. This is then reflected in the graph as it is split into exact 3-monthly intervals and so for those patients that had a censoring time of < 36 months, they do not get counted as at risk at the 36 months' time interval in the graph. We chose to estimate the actual time in months to censor patients on to reflect the analysis as accurately as possible.

FIGURE 6 Least-squares means plot over time by treatment arm for systolic and diastolic BP (mmHg). Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. On average, patients in both groups were taking an additional two antihypertensive medications at any given time point which were not ACEi/ARBs. These included medications such as calcium channel blockers, loop diuretic, thiazide diuretic, thiazide-like diuretic, potassium-sparing diuretic, mineralocorticoid receptor antagonist, alpha-blocker, beta-blocker, methyldopa, moxonidine, hydralazine or any other antihypertensive.

FIGURE 7 Least-squares means plot over time by treatment arm for systolic and diastolic BP (mmHg). Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. On average patients in both groups were taking an additional two antihypertensive medications at any given time point which were not ACEi/ARBs. These included medications such as calcium channel blockers, loop diuretic, thiazide diuretic, thiazide-like diuretic, potassium-sparing diuretic, mineralocorticoid receptor antagonist, alpha-blocker, beta-blocker, methyldopa, moxonidine, hydralazine or any other antihypertensive.

TABLE 10 The average number of these additional medications that patients in each arm were taking at each time point

Time point (months)	Summary	STOP	Continue
3	Mean (SD)	2.2 (1.1)	2.2 (0.9)
	Median (IQR)	2 (1–3)	2 (2–3)
	Minimum–maximum	1–5	1–6
6	Mean (SD)	2.3 (1)	2.3 (1)
	Median (IQR)	2 (2–3)	2 (2–3)
	Minimum–maximum	1–5	1–6
9	Mean (SD)	2.3 (1)	2.2 (1)
	Median (IQR)	2 (2–3)	2 (1–3)
	Minimum–maximum	1–5	1–6
12	Mean (SD)	2.3 (1)	2.1 (1)
	Median (IQR)	2 (2–3)	2 (1–3)
	Minimum–maximum	1–5	1–6
15	Mean (SD)	2.4 (1.1)	2.2 (1)
	Median (IQR)	2 (2–3)	2 (1–3)
	Minimum–maximum	1–6	1–6
18	Mean (SD)	2.3 (1.1)	2.1 (1)
	Median (IQR)	2 (1–3)	2 (1–3)
	Minimum–maximum	1–5	1–6
21	Mean (SD)	2.3 (1.1)	2.1 (1)
	Median (IQR)	2 (1–3)	2 (1–3)
	Minimum–maximum	1–5	1–6
24	Mean (SD)	2.3 (1.1)	2.1 (1)
	Median (IQR)	2 (1–3)	2 (1–3)
	Minimum–maximum	1–5	1–6
27	Mean (SD)	2.3 (1.1)	2 (1)
	Median (IQR)	2 (1–3)	2 (1–3)
	Minimum–maximum	1–5	1–6
30	Mean (SD)	2.2 (1.1)	2 (1)
	Median (IQR)	2 (1–3)	2 (1–3)
	Minimum–maximum	1–5	1–5
33	Mean (SD)	2.2 (1.1)	2 (1)
	Median (IQR)	2 (1–3)	2 (1–3)
	Minimum–maximum	1–5	1–5

TABLE 10 The average number of these additional medications that patients in each arm were taking at each time point (*continued*)

Time point (months)	Summary	STOP	Continue
36	Mean (SD)	2.1 (1.1)	1.9 (0.9)
	Median (IQR)	2 (1–3)	2 (1–2.5)
	Minimum–maximum	1–5	1–5

IQR, interquartile range.
Note
This summary excludes ACEi/ARBs since they were part of the randomised allocation. Included are medications such as calcium channel blockers, loop diuretic, thiazide diuretic, thiazide-like diuretic, K-sparing diuretic, mineralocorticoid receptor antagonist, alpha-blocker, beta-blocker, methyldopa, moxonidine, hydralazine or any other antihypertensive. Patients at any given time point may have been taking any of these additional medications.

TABLE 11 Six-minute walk test

				Mixed-effects linear regression
Time point	6-minute walk test	STOP	Continue	Estimated mean difference (95% CI)[a]
Baseline	**Did the 6-minute walk test**			
	Did the 6-minute walk test			
	N	206	203	
	No	26 (12.6%)	23 (11.3%)	
	Yes	180 (87.4%)	180 (88.7%)	
	Missing	0 (0%)	0 (0%)	
	If no, reason:			
	Clinical reason	10	7	
	Other reason	16	15	
	Missing	0	1	
	Distance (in metres covered)			
	N	180	180	
	Empirical mean (SD)	395 (168.1)	401 (154)	
1 year	**Did the 6-minute walk test**			
	N	187	189	
	No	67 (35.8%)	74 (39.2%)	
	Yes	116 (62%)	113 (59.8%)	
	Missing	6 (2.1%)	2 (1.1%)	
	If no, reason:			
	Clinical reason	13	19	
	Other reason	54	53	
	Missing	0	2	
	Distance (in metres covered)			
	N	116	113	
	Empirical mean (SD)	386 (124.9)	401.4 (141.3)	
	LS-Mean ± (SE)	398.5 ± (9.1)	396.3 ± (10.1)	

TABLE 11 Six-minute walk test (*continued*)

Time point	6-minute walk test	STOP	Continue	Mixed-effects linear regression
				Estimated mean difference (95% CI)[a]
2 years	**Did the 6-minute walk test**			
	N	170	170	
	No	81 (47.6%)	95 (55.9%)	
	Yes	87 (51.2%)	72 (42.4%)	
	Missing	2 (1.2%)	3 (1.8%)	
	If no, reason:			
	Clinical reason	14	22	
	Other reason	66	73	
	Missing	1	0	
	Distance (in metres covered)			
	N	87	72	
	Empirical mean (SD)	400.7 (130.7)	404.4 (121)	
	LS-Mean ± (SE)	413.9 ± (10.4)	397.4 ± (8.7)	
3 years	**Did the 6-minute walk test**			
	N	161	164	
	No	92 (57.1%)	117 (71.3%)	
	Yes	63 (39.1%)	46 (28%)	
	Missing	6 (3.7%)	1 (0.6%)	
	If no, reason:			
	Clinical reason	10	17	
	Other reason	82	99	
	Missing	0	1	
	Distance (in metres covered)			−17.6 (−57.4 to 22.1)
	N	63	46	
	Empirical mean (SD)	383 (180.3)	431.1 (114.7)	
	LS-Mean ± (SE)	393.9 ± (18.5)	411.5 ± (8.6)	

a Adjusted for all minimisation variables, baseline value, time and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust SEs used. Continue group is the reference category and so values > 0 for the mean difference indicate better outcomes for STOP group.

Note
Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

TABLE 12 KDQoL-SF v1.3 results at 3 years' time point

KDQoL SF v1.3	Summary statistic	STOP	Continue	Mixed-effects linear regression Estimated mean difference (95% CI)[a]
Burden of kidney disease	N	110	105	−4.05 (−10.92 to 2.81)
	Empirical mean (SD)	60.5 (29.1)	62.4 (33.2)	
	LS-Mean ± (SE)	57.23 ± (2.31)	61.28 ± (2.64)	
Cognitive function	N	110	104	−5.63 (−10.38 to −0.88)
	Empirical mean (SD)	79.5 (22.7)	82.1 (17.5)	
	LS-Mean ± (SE)	76.21 ± (1.93)	81.84 ± (1.44)	
Dialysis staff encouragement	N	51	45	−3.54 (−16.49 to 9.41)
	Empirical mean (SD)	91.2 (12.8)	91.4 (13.5)	
	LS-Mean ± (SE)	88.09 ± (3.33)	91.63 ± (5.60)	
Effects of kidney disease	N	108	105	−2.16 (−7.09 to 2.775)
	Empirical mean (SD)	78.7 (21.9)	79.2 (20.9)	
	LS-Mean ± (SE)	77.23 ± (1.69)	79.39 ± (1.84)	
Overall health rating	N	110	104	−1.13 (−6.45 to 4.19)
	Empirical mean (SD)	61.5 (23.3)	61.3 (20.3)	
	LS-Mean ± (SE)	60.51 ± (2.00)	61.64 ± (1.84)	
Participant satisfaction rating	N	58	58	−2.47 (−11.14 to 6.19)
	Empirical mean (SD)	84.5 (17.9)	83.3 (15.9)	
	LS-Mean ± (SE)	84.26 ± (3.42)	86.74 ± (2.75)	
Quality of social interaction	N	110	104	−3.53 (−8.48 to 1.42)
	Empirical mean (SD)	75.9 (20.5)	78.7 (17.6)	
	LS-Mean ± (SE)	75.08 ± (1.83)	78.61 ± (1.74)	
Sexual function	N	27	31	6.27 (−3.73 to 16.28)
	Empirical mean (SD)	85.2 (26.6)	80.2 (24.1)	
	LS-Mean ± (SE)	86.36 ± (3.36)	80.08 ± (3.81)	
Sleep	N	110	105	0.04 (−3.05 to 3.14)
	Empirical mean (SD)	43.6 (12.6)	45.7 (11.8)	
	LS-Mean ± (SE)	44.95 ± (1.16)	44.90 ± (1.06)	
Social support	N	109	105	−2.85 (−9.73 to 4.04)
	Empirical mean (SD)	79.2 (28.3)	81 (25.9)	
	LS-Mean ± (SE)	78.44 ± (2.61)	81.29 ± (2.36)	
Symptoms problems	N	110	104	−0.57 (−4.73 to 3.59)
	Empirical mean (SD)	79.7 (18.7)	77.5 (16.3)	
	LS-Mean ± (SE)	77.50 ± (1.60)	78.07 ± (1.37)	

TABLE 12 KDQoL-SF v1.3 results at 3 years' time point (*continued*)

KDQoL SF v1.3	Summary statistic	STOP	Continue	Mixed-effects linear regression Estimated mean difference (95% CI)[a]
Work status	N	110	105	1.48 (−6.16 to 9.11)
	Empirical mean (SD)	52.3 (36.7)	47.6 (36.3)	
	LS-Mean ± (SE)	51.74 ± (2.55)	50.26 ± (2.93)	

a Adjusted for minimisation variables, baseline score, time point and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust SEs used. Continue arm used as reference category in the model and values > 0 indicate better outcomes for STOP arm.

Note
Confidence interval widths have not been adjusted for multiplicity and therefore may not be used in place of hypothesis testing.

TABLE 13 Urine protein excretion (PCR) (mg/mmol)

Urine protein excretion	Time point	Summary statistic	STOP	Continue	Mixed-effects linear regression Estimated mean difference (95% CI)[a]
Urine protein excretion (mg/mmol)	Baseline	N	206	205	
		Empirical mean (SD)	178.6 (209.3)	172.8 (198.9)	
	3 months	N	162	164	
		Empirical mean (SD)	284.4 (283.9)	170.6 (180.3)	
		LS-Mean ± (SE)	258.0 ± (15.9)	149.5 ± (9.5)	
	6 months	N	134	152	
		Empirical mean (SD)	265.9 (309.4)	170.9 (193.6)	
		LS-Mean ± (SE)	247.4 ± (18.5)	149.4 ± (10.0)	
	9 months	N	124	139	
		Empirical mean (SD)	217.3 (246.2)	166.2 (182.3)	
		LS-Mean ± (SE)	217.1 ± (15.1)	155.4 ± (10.3)	
	12 months	N	138	141	
		Empirical mean (SD)	231.7 (248.5)	170.6 (194.7)	
		LS-Mean ± (SE)	230.8 ± (15.9)	163.6 ± (11.7)	
	15 months	N	101	111	
		Empirical mean (SD)	223.4 (256.3)	169.4 (212.1)	
		LS-Mean ± (SE)	222.6 ± (20.1)	164.6 ± (15.3)	

TABLE 13 Urine protein excretion (PCR) (mg/mmol) (*continued*)

Urine protein excretion	Time point	Summary statistic	STOP	Continue	Mixed-effects linear regression Estimated mean difference (95% CI)[a]
	18 months	N	108	110	
		Empirical mean (SD)	169.3 (194.1)	173.5 (209.5)	
		LS-Mean ± (SE)	196.2 ± (15.5)	172.2 ± (15.7)	
	21 months	N	98	101	
		Empirical mean (SD)	184.5 (248)	187 (249.6)	
		LS-Mean ± (SE)	212.4 ± (21.6)	181.1 ± (18.5)	
	24 months	N	107	111	
		Empirical mean (SD)	178.3 (195.8)	189.1 (284.7)	
		LS-Mean ± (SE)	203.7 ± (16.6)	186.4 ± (20.1)	
	27 months	N	76	78	
		Empirical mean (SD)	211 (276.1)	156.8 (217.8)	
		LS-Mean ± (SE)	251.4 ± (27.4)	159.2 ± (19.3)	
	30 months	N	77	75	
		Empirical mean (SD)	180 (293.7)	216.9 (255.3)	
		LS-Mean ± (SE)	225.4 ± (29.3)	222.7 ± (25.3)	
	33 months	N	63	64	
		Empirical mean (SD)	167.6 (352)	137.6 (213.1)	
		LS-Mean ± (SE)	205.0 ± (36.5)	153.5 ± (20.2)	
	36 months	N	71	85	−0.9 (−76.1 to 74.3)
		Empirical mean (SD)	159.9 (276.1)	176.3 (246.9)	
		LS-Mean ± (SE)	192.4 ± (31.3)	193.3 ± (21.7)	

a Adjusted for minimisation variables, baseline score, time point and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust SEs used. Continue group used as reference category in the model and so negative values indicate lower values in STOP group.

Note
Confidence interval widths have not been adjusted for multiplicity and hence may not be used in place of hypothesis testing.

There was a transient increase in proteinuria over the first year in those randomised to discontinue RAS inhibitors, but little difference was observed thereafter (the estimated mean difference at 3 year: −0.9 (95% CI −76 to 74) mg/mmol (see *Tables 9* and *13* and *Figure 8*).

Mean haemoglobin concentrations were similar for each group throughout the 3-year follow-up (see *Tables 9* and *14*).

FIGURE 8 Least-squares means plot over time by treatment arm (urine protein excretion –uPCR in mg/mmol). Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

TABLE 14 Haemoglobin (g/l)

Haemoglobin (g/l)	Time point	Summary statistic	STOP	Continue	Mixed-effects linear regression Estimated mean difference (95% CI)[a]
Haemoglobin	Baseline	N	205	202	
		Empirical mean (SD)	117 (15)	117 (14)	
	3 months	N	194	195	
		Empirical mean (SD)	118 (17)	115 (14)	
		LS-Mean ± (SE)	119 ± (0.8)	116 ± (0.7)	
	6 months	N	190	186	
		Empirical mean (SD)	117 (1.7)	114 (14)	
		LS-Mean ± (SE)	117 ± (0.09)	115 ± (0.8)	
	9 months	N	186	183	
		Empirical mean (SD)	118 (17)	115 (14)	
		LS-Mean ± (SE)	118 ± (1.0)	115 ± (0.8)	
	12 months	N	181	182	
		Empirical mean (SD)	118 (17)	115 (14)	
		LS-Mean ± (SE)	117 ± (1.0)	115 ± (0.9)	

continued

TABLE 14 Haemoglobin (g/l) (*continued*)

Haemoglobin (g/l)	Time point	Summary statistic	STOP	Continue	Mixed-effects linear regression Estimated mean difference (95% CI)[a]
	15 months	*N*	168	171	
		Empirical mean (SD)	117 (17)	115 (15)	
		LS-Mean ± (SE)	116 ± (1.0)	116 ± (1.0)	
	18 months	*N*	165	167	
		Empirical mean (SD)	119 (16)	116 (15)	
		LS-Mean ± (SE)	118 ± (1.1)	116 ± (1.0)	
	21 months	*N*	165	164	
		Empirical mean (SD)	118 (16)	116 (16)	
		LS-Mean ± (SE)	118 ± (1.0)	117 ± (1.1)	
	24 months	*N*	166	160	
		Empirical mean (SD)	117 (18)	116 (17)	
		LS-Mean ± (SE)	116 ± (1.2)	116 ± (1.2)	
	27 months	*N*	155	155	
		Empirical mean (SD)	117 (18)	117 (18)	
		LS-Mean ± (SE)	116 ± (1.2)	116 ± (1.2)	
	30 months	*N*	153	155	
		Empirical mean (SD)	118 (19)	117 (18)	
		LS-Mean ± (SE)	117 ± (1.4)	117 ± (1.2)	
	33 months	*N*	144	145	
		Empirical mean (SD)	119 (18)	118 (16)	
		LS-Mean ± (SE)	118 ± (1.4)	118 ± (1.1)	
	36 months	*N*	153	161	0.4 (−3.3 to 4.0)
		Empirical mean (SD)	121 (19)	120 (19)	
		LS-Mean ± (SE)	119 ± (1.3)	119 ± (1.0)	

a Adjusted for minimisation variables, baseline score, time point and treatment by time interaction. A compound symmetry covariance structure is assumed in the model and robust SEs used. Continue group used as reference category in the model and so negative values indicate lower values in STOP group.

Note
Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.

Chapter 6 Safety and harms

Safety

There were 107 (51.9%) participants who had a reported SAE recorded in the discontinue RAS inhibitor group and 101 (49.3%) participants in the continue RAS inhibitor group. This amounted to a total of 490 SAEs reported (237 and 253 in the discontinue and continue RAS inhibitor groups, respectively), of which 21 may have been related to the trial intervention, with similar numbers for each group (see *Tables 9* and *15–19*). Serious adverse CV, vascular and heart failure events were also similar across the two groups.

TABLE 15 Adverse events part 1 for STOP ACEi trial

AEs	STOP		Continue		Total	
	N of events	N of participants with an event	N of events	N of participants with an event	N of events	N of participants with an event
CV disease						
Hospitalisation for heart failure	5	5	6	6	11	11
Myocardial infarction (ST elevation)	2	2	2	2	4	4
Myocardial infarction (non-ST elevation)	5	4	7	6	12	10
Stroke	7	6	5	5	12	11
Heart failure (clinician's opinion)						
Yes	19	8	21	13	40	21
Other CV disease						
Angina	7	5	4	4	11	9
Coronary intervention (PCI)	6	5	3	3	9	8
Hypertension	31	22	13	12	44	34
Atrial fibrillation/Flutter	7	7	5	4	12	11
Venous thromboembolism	3	2	2	2	5	4
Peripheral vascular disease	0	0	1	1	1	1
Other CV condition	16	16	19	17	35	33
Diabetes						
Type 1 diabetes mellitus	1	1	3	2	4	3
Type 2 diabetes mellitus	10	10	9	8	19	18
Malignancy						
Yes	18	14	16	13	34	27

TABLE 15 Adverse events part 1 for STOP ACEi trial (*continued*)

AEs	STOP		Continue		Total	
	N of events	*N of participants with an event*	*N of events*	*N of participants with an event*	*N of events*	*N of participants with an event*
Gastrointestinal						
Bloating, abdominal distention or abdominal pain	25	16	18	17	43	33
Constipation	27	21	31	20	58	41
Dyspepsia	8	6	3	3	11	9
Gastritis	3	2	2	2	5	4
Loose stools/diarrhoea	38	27	31	27	69	54
Nausea/vomiting	45	35	37	27	82	62
Ulceration	3	3	1	1	4	4
Other gastrointestinal condition	23	23	29	29	52	52

TABLE 16 Adverse events part 2 for STOP ACEi trial

AEs	STOP (*N* = 206)		Continue (*N* = 205)		Total (*N* = 411)	
	N of events	*N of participants with an event*	*N of events*	*N of participants with an event*	*N of events*	*N of participants with an event*
Musculoskeletal or connective disorders						
Fractures	13	12	10	9	23	21
Osteoporosis	1	1	3	3	4	4
Osteopenia	2	2	1	1	3	3
Other musculoskeletal or connective tissue disorder	57	56	46	46	103	102
Infection						
Urinary tract infection	66	38	52	22	118	60
Cytomegalovirus	1	1	0	0	1	1
Herpes simplex virus	1	1	0	0	1	1
Varicella zoster virus	6	6	3	3	9	9
Other infection	135	130	152	138	287	268
Pulmonary disease						
Chronic obstructive pulmonary disease (COPD)	3	3	3	3	6	6
Other pulmonary disease	15	15	10	10	25	25

TABLE 16 Adverse events part 2 for STOP ACEi trial (*continued*)

AEs	STOP (N = 206)		Continue (N = 205)		Total (N = 411)	
	N of events	*N of participants with an event*	*N of events*	*N of participants with an event*	*N of events*	*N of participants with an event*
Other						
Psychosis	1	1	1	1	2	2
Gout	31	20	34	22	65	42
Breathlessness	48	39	43	31	91	70
Peripheral oedema	57	42	19	17	76	59
Anaemia	23	19	27	22	50	41
Leucopenia	1	1	1	1	2	2
Thrombocytopenia	1	1	0	0	1	1
Endocrine or metabolic disorder	6	6	5	3	11	9
Cataracts	17	12	9	6	26	18
Other	467	427	534	513	1001	940

TABLE 17 Number of participants with SAEs

Participants experiencing an SAE	STOP (N = 206)	Continue (N = 205)	Total (N = 411)
No	99 (48.1%)	104 (50.7%)	203 (49.4%)
Yes	107 (51.9%)	101 (49.3%)	208 (50.6%)
If yes, participants with exactly:			
1 SAE	50	41	91
2 SAEs	26	21	47
3 SAEs	12	20	32
4 SAEs	8	7	15
5 SAEs	5	3	8
6 SAEs	1	5	6
7 SAEs	4	2	6
8 SAEs	1	0	1
9 SAEs	0	0	0
10 SAEs	0	0	0
11 SAEs	0	1	1
12 SAEs	0	1	1
Total SAEs	237	253	490

TABLE 18 Serious adverse events by common terminology criteria for adverse events (CTCAE), part 1

CTCAE term	STOP	Continue	Total
Anaemia	4	2	6
Blood and lymphatic system disorders – other, specify	2	0	2
Atrial fibrillation	0	4	4
Atrial flutter	0	1	1
Atrioventricular block complete	2	0	2
Cardiac arrest	1	0	1
Chest pain – cardiac	3	6	9
Conduction disorder	0	1	1
Heart failure	10	8	18
Left ventricular systolic dysfunction	0	1	1
Myocardial infarction	9	8	17
Myocarditis	0	1	1
Cardiac disorders – other, specify	1	2	3
Papilledema	0	1	1
Abdominal distension	0	1	1
Abdominal pain	1	2	3
Colonic obstruction	1	0	1
Colonic perforation	1	0	1
Constipation	0	3	3
Diarrhoea	5	3	8
Duodenal haemorrhage	1	0	1
Duodenal obstruction	0	1	1
Duodenal ulcer	2	0	2
Dysphagia	1	0	1
Oesophageal ulcer	0	1	1
Oesophagitis	3	1	4
Gastric haemorrhage	0	2	2
Gastritis	1	1	2
Gastrointestinal pain	0	1	1
Hemorrhoidal haemorrhage	0	1	1
Lower gastrointestinal haemorrhage	1	1	2
Nausea	0	1	1
Pancreatitis	0	1	1
Rectal haemorrhage	2	3	5
Small intestinal obstruction	1	0	1
Small intestinal stenosis	0	2	2

TABLE 18 Serious adverse events by common terminology criteria for adverse events (CTCAE), part 1 (*continued*)

CTCAE term	STOP	Continue	Total
Upper gastrointestinal haemorrhage	1	0	1
Visceral arterial ischaemia	0	1	1
Vomiting	1	5	6
Gastrointestinal disorders – other, specify	3	2	5
Disease progression	1	0	1
Oedema limbs	0	1	1
Fatigue	1	0	1
Fever	1	1	2
Flu-like symptoms	0	2	2
Generalised oedema	2	0	2
Multiorgan failure	1	1	2
Sudden death NOS	0	1	1
General disorders and administration site conditions – other, specify	0	1	1
Cholecystitis	1	1	2
Hepatobiliary disorders – other, specify	0	1	1
Anaphylaxis	1	0	1
Autoimmune disorder	0	1	1
Abdominal infection	1	2	3
Appendicitis	0	1	1
Bladder infection	0	1	1
Bone infection	0	4	4
Bronchial infection	3	3	6
Catheter-related infection	4	0	4
Device-related infection	4	2	6
Endocarditis infective	1	1	2
Joint infection	1	1	2
Kidney infection	2	4	6
Lung infection	20	20	40
Lymph gland infection	2	0	2

TABLE 19 Serious adverse events by CTCAE, part 2

CTCAE term	STOP	Continue	Total
Pelvic infection	0	1	1
Peritoneal infection	8	10	18
Pharyngitis	0	1	1
Sepsis	1	2	3
Shingles	0	1	1
Skin infection	4	4	8
Small intestine infection	2	0	2
Soft-tissue infection	3	2	5
Upper respiratory infection	0	1	1
Urinary tract infection	15	8	23
Wound infection	1	2	3
Infections and infestations – other, specify	5	5	10
Fall	2	5	7
Fracture	2	5	7
Hip fracture	2	0	2
Vascular access complication	4	3	7
Alkaline phosphatase increased	0	1	1
Creatinine increased	2	1	3
International normalised ratio increased	1	0	1
Acidosis	1	0	1
Dehydration	1	0	1
Glucose intolerance	1	0	1
Hypercalcaemia	1	0	1
Hyperglycaemia	0	1	1
Hyperkalaemia	2	4	6
Hypocalcaemia	2	1	3
Hypoglycaemia	1	0	1
Hyponatraemia	1	0	1
Hypophosphataemia	0	1	1
Arthralgia	1	0	1
Arthritis	0	3	3
Chest wall pain	2	1	3
Pain in extremity	2	0	2
Treatment-related secondary malignancy	1	0	1
Neoplasms benign, malignant and unspecified (incl. cysts and polyps) – other, specify	2	3	5
Cognitive disturbance	0	2	2

TABLE 19 Serious adverse events by CTCAE, part 2 (continued)

CTCAE term	STOP	Continue	Total
Headache	1	1	2
Seizure	2	1	3
Stroke	3	2	5
Syncope	3	0	3
Transient ischaemic attacks	0	1	1
Confusion	0	2	2
Depression	1	0	1
Acute kidney injury	6	8	14
CKD	7	7	14
Haematuria	0	2	2
Renal calculi	0	1	1
Urinary retention	1	0	1
Urinary tract obstruction	2	3	5
Renal and urinary disorders – other, specify	5	6	11
Bronchospasm	0	1	1
Dyspnoea	2	1	3
Epistaxis	3	0	3
Pleural effusion	2	8	10
Pneumonitis	2	0	2
Pulmonary oedema	1	2	3
Pulmonary fibrosis	0	1	1
Respiratory failure	1	1	2
Skin and subcutaneous tissue disorders – other, specify	1	0	1
Social circumstances – other, specify	0	2	2
Surgical and medical procedures – other, specify	8	3	11
Haematoma	0	2	2
Hypertension	2	0	2
Hypotension	1	3	4
Lymphocele	1	0	1
Peripheral ischaemia	4	3	7
Thromboembolic event	2	4	6
Vascular disorders – other, specify	3	3	6
Total	**237**	**253**	**490**

The number and percentage of participants experiencing at least one SAE are reported by treatment group. Where participants experienced more than one SAE, these data are presented and summarised as count data by treatment group, that is number of participants that experienced exactly 1 SAE, 2 SAEs, 3 SAEs, etc.

One suspected unexpected serious adverse reaction (SUSAR), a possible transient ischaemic attack, was reported approximately 15 months after the participant was randomised to discontinue RAS inhibitor. This was initially reported to the Medicines Health Regulatory Authority (MHRA) as required in the protocol as it was deemed by the local investigator to be a SUSAR. The final clinical details and adjudication from the principle local investigator of this SAE in the discontinue RAS inhibitor group were that it was deemed a chest infection (which the CI concurred with) and therefore in the table it appears as a lung infection.

The early changes in BP, as a result of discontinuing RAS inhibitors, were recorded as recognised AEs of discontinuing such a drug. In total, there were 31 events in the discontinue RAS inhibitor group and 13 in the continue RAS inhibitor group.

A total of six cases of hyperkalaemia based on CTCAE were recorded (see *Tables 18* and *19*), two in the discontinue RAS inhibitor group and four in the continue RAS inhibitor group.

Chapter 7 Discussion and conclusions

Summary of main findings

The STOP-ACEi trial evaluated discontinuation of RAS inhibitors in patients with advanced and progressive CKD. The trial excluded a clinically relevant improvement in eGFR after discontinuing RAS inhibitors for such patients, overall or in pre-specified subgroups by age, severity of CKD, diabetes, proteinuria or BP. The number of patients developing ESKD or getting KRT and the rate of CV events and death during 3 years of follow-up was similar for those who discontinued or continued RAS inhibitors. Systolic and diastolic BP and proteinuria were greater over the first year of follow-up in those randomised to discontinue RAS inhibitors, but there was little difference thereafter, reflecting initiation of antihypertensive agents other than RAS inhibitors. No differences in quality of life or exercise capacity were observed for those who discontinued or continued RAS inhibitors.

There are conflicting data about whether RAS inhibitors are renoprotective in advanced CKD. Two earlier post hoc analyses of RAS inhibitor use against placebo including a small proportion of patients with advanced CKD suggested that RAS inhibitors were beneficial in advanced CKD,[15,16] while a small (*n* = 52) observational study reported that withdrawing RAS inhibitors from patients with advanced CKD led to a mean increase in eGFR of 10 (16–27) ml/minute/1.73 m^2 over 12 months. This study showed that there was an increase or stabilisation in eGFR in 48 of the 52 patients.[13] Analysis of a large observational registry also suggested that stopping RAS inhibitors reduced progression to ESKD.[18] Our trial suggests that discontinuing RAS inhibitors in patients with advanced CKD does not improve kidney function, quality of life or exercise capacity.

For patients with CKD, the rate of decline in eGFR is a good predictor of developing ESKD[53] and is increasingly used as an end point for clinical trials. Preservation of eGFR slope by > 0.75 ml/minute/1.73 m^2 per year over 3 years predicts a clinically relevant delay of CKD progression.[54] This measure has been used as a surrogate outcome in several recent randomised trials.[53–57] Although RAS inhibitors slow the decline in eGFR for patients with mild or moderate CKD,[11,15,16] our trial suggests that they might not do so for patients with advanced and progressive CKD. Of note, BP control was similar for each group during follow-up. Assuming that control of BP is important for this population, our trial suggests that choice of guideline-recommended antihypertensive agent may not be important.

Randomised trials that have specifically assessed the effect of RAS inhibitors on CV risk in patients with advanced non-dialysis CKD are lacking. However, in a large observational registry, Fu *et al.* reported an increase in major CV events and mortality for patients who discontinued RAS inhibitors.[18] In a separate retrospective cohort study, Qiao *et al.*[20] also found that discontinuing RAS inhibitors increased the risk of CV events and mortality and did not reduce the need for KRT. Our trial lacked sufficient power to investigate the effect of withdrawing RAS inhibitors on CV events or mortality. However, because our trial suggests that there is no advantage in discontinuing RAS inhibitors from the perspective of kidney function, there is little rationale to conduct a larger randomised trial to investigate CV safety.

Limitations

There were limitations in the process of recruitment to the study. We targeted those with progressive disease as we anticipated this group had the greatest potential to see benefit from the intervention and were mindful of equipoise issues for potential participants and recruiting clinicians not wanting to 'rock the boat' if disease was stable. The European QUALity Study on treatment in advanced CKD (EQUAL) recently reported on patients over the age of 65 years and with an eGFR < 20 ml/minute/1.73 m^2.

Average eGFR decline was 1.82 ml/minute/1.73 m^2 in men and 0.91 ml/minute/1.73 m^2 in women.[68] This might require further study.

Additionally, there has been a trend of discontinuation of RAS inhibitors, often in primary care, based on the view that this may stabilise or improve kidney function and delay the need for KRT. This was despite a paucity of high-quality supporting evidence. This would also have rendered participants ineligible for the trial, often before there was opportunity for them to consider participation in the trial.

We did not specify any nutritional requirements in the trial but recognise that diet is an important aspect in patients with advanced CKD. All kidney services have specialist nutrition support for patients with advanced CKD to support management consistent with NICE guidance, which is based on a detailed evidence evaluation.[63] The NICE guidance 1.4.7 suggests one offers dietary advice about potassium, phosphate, calorie and salt intake appropriate to the severity of CKD and also for guidance 1.4.8 it suggests if dietary intervention is agreed, it should be provided alongside education, detailed dietary assessment and supervision to ensure malnutrition is prevented and finally guidance 1.4.9 suggests one does not offer low-protein diets (dietary protein intake < 0.6–0.8 g/kg/day) to adults with CKD.[63] This is in contradistinction to the most recent 2020 update of the KDOQI clinical practice guideline for nutrition in CKD which does advise low-protein diets in patients with CKD where the evidence is graded at 2c for people without diabetes and graded as 'opinion' for people with diabetes.[69] Hence, this decision on diet management was left to the local investigator/responsible clinician.

The open-label nature of the trial may have affected clinical care and subjective end points including quality of life and exercise capacity. The findings may not generalise to patients with higher levels of proteinuria (e.g. uPCR > 300 mg/mmol). The median baseline value was 115 mg/mmol suggesting few cases had nephrotic syndrome.

There was an imbalance in adherence in the two arms, with a progressive difference developing through the trial. Up to 15 months this was similar in both groups but by the end of the 3 years 23% of patients on the continue arm had discontinued (vs. 12% in the discontinue arm who were taking). This may impact the result by the end of trial. A per-protocol analysis was considered but discounted by the independent data monitoring committee and their statistician. This might represent a potential for confounding but the percentage of non-adherent participants in our study is not dissimilar to other clinical trials.

Numerically more patients who stopped RAS inhibitors progressed to ESKD; a larger trial might have demonstrated an advantage to continuing with RAS inhibitors.

Equity, diversity and inclusivity

In considering gender, age, ethnicity and socioeconomic status, the following can be commented on:

Chronic kidney disease affects women more than men (15.4% vs. 12.8% in 2011–2), but men are 1.5 times more likely to develop ESKD compared with women across racial/ethnic groups.[70,71] The reasons for this sex-related disparity are not well understood even after adjustment for sociodemographic characteristics, baseline kidney function, CV risk factors, medications and markers of bone mineral metabolism. The prevalence increases with age; women with CKD are older than men with CKD, but older patients are less likely to progress to ESKD.[70,71] The participants in the present trial demonstrated the expected ratio of men to women. Biologic sex was reported by the participants during the baseline assessment, they were asked, female, male, or no answer. Gender was not asked. Baseline age, sex, body mass index, BP, diabetes prevalence and the proportion of current smokers were all similar to UK Renal Registry data.[72]

Chronic kidney disease affects individuals of black and South Asian ethnicity disproportionately in the USA and UK. In the USA 13% of the population are black, yet 30% of the ESKD population are black and the black population has a 3.5-fold greater risk of progression and a higher mortality, although this disparity is reducing. The proportion of black and South Asian patients who underwent randomisation overall was small at 6% and 7%, respectively. Therefore, the proportion of non-white participants was similar to the current prevalence in the UK 2019 Renal Registry Report, which although incomplete (only 25% of units provided data) had 2.6% black and 8.5% Asian with CKD and 13.4% Asian and 7.4% black with ESKD.[72]

In the UK and other countries, CKD develops at a younger age with certain genetic disorders such as Alport syndrome which again impacts males more than females with earlier progression to ESKD. In addition, non-vascular causes in individuals with black and South Asian ethnicity tend to be younger than those with white ethnicity.

Lower socioeconomic status, education and income directly impact the prevalence of CKD and tend to occur more in non-white populations in the UK. Women also are more likely to have adverse risk factors, including lower socioeconomic status and physical activity.

Implications for health care

The results of this trial have already had the kidney and cardiology world talking. These results will improve equality of care, ensuring all patients receive optimal care. The focus now for health care is on updating clinical guidelines in the UK and worldwide as the results are relevant to practice in disciplines including general medicine, hypertension, cardiology and nephrology and in reassessing CV risk management.

Conclusions

As delivered, the STOP ACEi programme did not impact the change in eGFR over 3 years; nor did it impact CV events or mortality. Other secondary outcomes (e.g. BP, quality of life) were also similar across groups. In conclusion, discontinuing RAS inhibitors in patients with advanced and progressive CKD did not lead to a clinically relevant change in eGFR or difference in the rate of long-term decline in eGFR. If indicated for the treatment of hypertension, proteinuria or CV disease, RAS inhibitors should not be discontinued just because eGFR is low.

Future work and recommendations for research

Future work should initially focus on updating clinical guidelines in the UK and worldwide as the results are relevant to practice in disciplines including general medicine, hypertension, cardiology and nephrology and in reassessing CV risk management. With the development of newer therapies such as SGLT2 receptor antagonists, combination therapies will require further examination in this population. Future studies also need to evaluate whether there are subgroups of patients who may benefit from RAS inhibition withdrawal, and also whether there is scope to optimise the intervention to improve compliance and effectiveness. This should include further qualitative work.

A further analysis, in addition to the prespecified analyses, may be undertaken if new eGFR equations are introduced into routine clinical practice. NICE have recommended the removal of black ethnicity correction factor from the eGFR equation as it is now recognised that this adjustment is problematic across different populations of black ethnicity. A major weakness of using a single black ethnicity correction factor is that it covers over 1 billion people with broad and diverse backgrounds. In

continental African populations, there is substantial evidence that an adjustment factor is not required. For example, in a cohort of 93 healthy Congolese participants, both MDRD and CKD-EPI (creatinine only and creatinine-cystatin C) equations demonstrated significantly reduced bias compared to GFR, measured using plasma clearance of iohexol, by removing the ethnicity adjustment factor.[73] Cystatin C containing CKD-EPI equations also performed better than creatinine equations alone, suggesting that serum creatinine concentration is more dependent on non-GFR factors.[74] Similar results have recently been reported in a UK study.[75]

A new CKD-EPI equation without ethnicity adjustment (CKD-EPI 2021) has been published.[76] However, this is not recommended in the UK as it has been developed in North American populations and has not been validated with UK and other populations. This equation underestimates eGFR in black people (median 3.6 ml/minute/1.73 m^2: 1.8–5.5) and overestimates in non-black people (median 3.9 ml/minute; 3.4–4.4). Using cystatin C and creatinine equations increases the precision of eGFR in respect to measured GFR.[67] If new equations are developed that are recommended in the UK, then a re-analysis using these equations could be performed.

Acknowledgements

We are grateful to the research nurses and research assistants and all the PIs who facilitated completion of this important clinical trial. We are particularly grateful to all the participants who kindly consented to be part of this landmark trial.

Contributions of authors

Sunil Bhandari (https://orcid.org/0000-0002-0996-9622) (Professor of Nephrology, Chief investigator) conceived and designed the study, interpreted and contextualised the data, wrote the first draft of the report and revised the draft report.

Samir Mehta (https://orcid.org/0000-0001-7096-513X) (Statistician) provided statistical support throughout the study and developed and led the planned statistical analyses, and revised the draft report.

Arif Khwaja (https://orcid.org/0000-0002-4690-3649) (Consultant Nephrologist, Co-investigator) interpreted and contextualised the data, and revised the draft report.

John Cleland (https://orcid.org/0000-0002-1471-7016) (Professor of Cardiology, Cardiology Expert) conceived and designed the study, interpreted and contextualised the data, and revised the draft report.

Natalie Ives (https://orcid.org/0000-0002-1664-7541) (Senior Statistician) conceived and designed the study, provided statistical support throughout the study and developed and led the planned statistical analyses, and revised the draft report.

Elizabeth Brettell (https://orcid.org/0000-0002-0669-3085) (Trials Management Team Leader) revised the draft report.

Marie Chadburn (https://orcid.org/0000-0003-0635-6852) (Trials Management Team Leader) revised the draft report.

Paul Cockwell (https://orcid.org/0000-0003-1975-266X) (Professor of Nephrology, Co-investigator) conceived and designed the study, interpreted and contextualised the data, and revised the draft report

All authors approved the final report.

Publications

Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, *et al.* Multicentre randomised controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. *Nephrol Dial Transplant* 2016;**31**(2):255–61.

Bhandari S, Mehta A, Khwaja A, Cleland JGF, Ives N, Brettell E, *et al.*; for the STOP ACEi trial investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. *N Engl J Med* 2022;**387**(22):2021–32. https://doi.org/10.1056/NEJMoa2210639. Epub ahead of print.

Ethics statement

Ethical approval for the STOP-ACEi trial was granted by the National Research Ethics Service Committee Yorkshire and the Humber—Leeds East (13/YH/0394) on 29 January 2014.

Governance

We are indebted to the following members of the Data Monitoring and Ethics Committee (DMEC) for their oversight of the trial; Dr John Firth (chairperson), Dr Paul Kalra (cardiologist) and Mrs Merryn Voysey (independent statistician).

We sincerely thank the following members of the TSC and their support during the work and valuable guidance: Professor Richard Haynes (chairperson) and Professor Nick Selby. I particularly would wish to thank our patient representative Christopher Allison, who unfortunately passed away just before the end of the trial completion. His helpful contribution was invaluable.

Sponsor and monitor

Hull University Teaching Hospitals NHS Trust Research and Development Department.

Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to anonymised data may be granted following review. Hull University Teaching Hospitals NHS Trust organisation is committed to handling all personal information in line with the UK Data Protection Act (2018) and the General Data Protection Regulation (EU GDPR) 2016/679.

Information Governance statement

Under the Data Protection legislation, Hull University Teaching Hospitals NHS Trust is the Data Controller, and you can find out more about how we handle personal data, including how to exercise your individual rights and the contact details for our Data Protection Officer here: www.hey.nhs.uk/privacy/data-protection/

Department of Health and Social Care disclaimer

This publication presents independent research commissioned by the NIHR. The views expressed in this publication are those of the authors and not necessarily of the National Health Service, the NIHR or the Department of Health. The funders had no role in the design, collection, analysis, interpretation of the data, or writing of this protocol.

References

1. Levey AS, Andreoli SP, Dubose T, Provenzano R, Collins AJ. Chronic kidney disease: common, harmful and treatable-world kidney day. *Am J Nephrol* 2007;**27**:108–12.

2. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, *et al*.; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010;**375**(9731):2073–81.

3. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, *et al*.; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int* 2011;**80**(1):93–104.

4. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, *et al*. Prediction of ESRD and death among people with CKD: the chronic kidney impairment in birmingham (CRIB) prospective cohort study. *Am J Kidney Dis* 2010;**56**(6):1082–94.

5. Quinn MP, Cardwell CR, Kee F, Maxwell AP, Savage G, McCarron P, Fogarty DG. The finding of reduced estimated glomerular filtration rate is associated with increased mortality in a large UK population. *Nephrol Dial Transplant* 2011;**26**(3):875–80.

6. Caskey FJ, Wordsworth S, Ben T, de Charro FT, Delcroix C, Dobronravov V, *et al*.; EURODICE group. Early referral and planned initiation of dialysis: what impact on quality of life? *Nephrol Dial Transplant* 2003;**18**(7):1330–8.

7. Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, *et al*. Early referral strategies for management of people with markers of kidney disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. *Health Technol Assess* 2010;**14**(21):1–184.

8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med* 1993;**329**(20):1456–62.

9. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, *et al*.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001;**345**(12):851–60.

10. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, *et al*.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;**345**(12):861–9.

11. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, *et al*. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in Progressive Renal Insufficiency Study Group. *N Engl J Med* 1996;**334**(15):939–45.

12. Ambrosiom E, Borghi CM, Magnam BT. Effect of the angiotensin-converting–enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. *N Engl J Med* 1995;**332**(2):80–5.

13. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. *Nephrol Dial Transplant* 2010;**25**(12):3977–82.

14. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, *et al.* Efficacy and safety of benazepril for advanced chronic renal insufficiency. *N Engl J Med* 2006;**354**(2):131–40.

15. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. *J Am Soc Nephrol* 2001;**12**(12):2832–7.

16. Remuzzi G, Ruggenenti P, Perma A, Dimitrov BD, de Zeeuw D, Hille DA, *et al.* RENAAL Study Group. Continuum of renoprotection with losartan at all stages of types 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. *J Am Soc Nephrol* 2004;**15**:3117–25.

17. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, *et al.* ACEI/ARB use and mortality in patients with CKD. *J Am Coll Cardiol* 2014;**63**(7):650–8.

18. Fu EL, Evans M, Clase CM, Tomlinson LA, van Diepen M, Dekker FW, Carrero JJ. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide Study. *J Am Soc Nephrol* 2021;**32**:424–35.

19. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, *et al.* RAS inhibitors and kidney and cardiovascular outcomes in patients with CKD. Bayesian Network metanalysis of RCTs. *Am J Kidney Dis* 2016;**67**(5):728–41.

20. Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, *et al.* Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with eGFR. *JAMA Intern Med* 2020;**180**(5):718–26.

21. Cheng J, Zhang W, Zhang X, Han F, Li X, He X, *et al.* Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. *JAMA Intern Med* 2014;**174**(5):773–85.

22. Strippoli GFM, Craig JC, Schena FPT. Number, quality, and coverage of RCTs in nephrology. *J Am Soc Nephrol* 2004;**15**(2):411–9.

23. Ahmed A, Jorna T, Bhandari S. Should we STOP angiotensin converting enzyme inhibitors/angiotensin receptor blockers in advanced kidney disease? *Nephron* 2016;**133**(3):147–58.

24. Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). *Kidney Int Suppl* 2004;**66**(92):S90–6.

25. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;**29**(14):977–86.

26. Hsu CY, Bates DW, Kuperman GJ, Curhan GCB. Pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. *Am J Hypertens* 2001;**14**(12):1219–25.

27. Indermitte J, Burkolter S, Drewe J, Krahenbuhl S, Hersberger KE. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. *Drug Saf: Int J Med Toxicol Drug Exp* 2007;**30**(1):71–80.

28. Dagenais GR, Yusuf S, Bourassa MG, Yi Q, Bosch J, Lonn EM, *et al.*; HOPE Investigators. Effects of ramipril on coronary events in high-risk persons: results of the heart outcomes prevention evaluation study. *Circulation* 2001;**104**(5):522–6.

29. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, *et al.*; LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint

reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;**359**(9311):995–1003.

30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;**288**(23):2981–97.

31. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. *Cochrane Database Syst Rev* 2006;**18**(4). URL: www.ncbi.nlm.nih.gov/pmc/articles/PMC6956646/ (accessed 2 September 2022).

32. Kidney Disease improving global outcomes 2012 (KDIGO). Clinical practice guidelines for the management of blood pressure in chronic kidney disease. *Kid Inter Suppl* 2012:337–414. URL: https://kdigo.org/guidelines/blood-pressure-in-ckd/ (accessed 5 August 2022).

33. Thomas MC, Jerums G, Tsalamandris C, Macisaac R, Panagiotopoulos S, Cooper ME; MDNSG Study Group. Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes. *Kidney Int* 2005;**67**(6):2494–9.

34. Morimoto T, Gindini TK, Fiskio JM, Seger AC, So JW, Cook EF, *et al*. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. *J Eval Clin Pract* 2004;**10**(4):499–509.

35. Mann JF, Schmieder RE, Mcqueen M, Dyal L, Schumacher H, Pogue J, *et al*.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet* 2008;**372**(9638):547–53.

36. Nistor I, De Sutter J, Drechsler C, Goldsmith D, Soler MJ, Tomson C, *et al*. Effect of renin–angiotensin–aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. *Nephrol Dial Transplant* 2018;**33**(1):12–22.

37. Tomlinson LA, Abel GA, Chaudhry AN, Tomson CR, Wilkinson IB, Roland MO, Payne RA. ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admission with acute kidney injury: a longitudinal ecological study. *PLOS ONE* 2013;**8**(11):e78465.

38. Tomson C, Tomlinson LA. Stopping RAS inhibitors to minimize AKI: more harm than good? *Clin J Am Soc Nephrol* 2019;**14**(4):617–9.

39. Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. *Semin Dial* 2007;**20**(6):566–9.

40. Kalantar-Zadeh K, Kovesdy CP, Derose SF, Horwich TB, Fonarow GC. Racial and survival paradoxes in chronic kidney disease. *Nat Clin Pract Nephrol* 2007;**3**(9):493–506.

41. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomised aldactone evaluation study. *N Engl J Med* 2004;**351**(6):543–51.

42. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J. Change in estimated GFR associates with coronary heart disease and mortality. *J Am Soc Nephrol* 2009;**20**(12):2617–24.

43. Neovius M, Jacobson SH, Eriksson JK, Elinder C-G, Hylander B. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. *BMJ Open* 2014;**4**(2):e004251.

44. Evans M, Carreri JJ, Szummer K, Åkerblom A, Edfors R, Spaak J, *et al*. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction. *J Am Coll Cardiol* 2016;**67**:1687–97.

45. Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, Lechat P. Prevention of cardiovascular events in ESRD. Results of a RCT of fosinopril and implications for future studies. *Kidney Int* 2006;**70**:1318–24.

46. Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined ACEi and ARB associate with increased of cardiovascular death in haemodialysis patients. *Kidney Int* 2011;**80**:978–85.

47. Hsu TW, Liu JS, Hung SC, Kuo K-L, Chang Y-K, Chen Y-C, *et al*. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with pre-dialysis advanced chronic kidney disease, hypertension, and anaemia. *JAMA Intern Med* 2014;**174**(3):347–54.

48. Mahmoudpour SH, Asselbergs FW, Souverein PC, de Boer A, MAtland-van der Zee AH. Prescription patterns of ACEi for various indications: a UK population-based study. *Br J Cin Pharmacol* 2018;**84**(10):2365–72.

49. Schmidt M, Mansfield KE, Bhaskaran K, Nitsch D, Sørensen HT, Smeeth L, Tomlinson LA. Adherence to guidelines for creatinine and potassium monitoring and discussion following RAS blockade: a UK general practice- based cohort study. *BMJ Open* 2017;**7**(1):e012818.

50. Edner M, Benson L, Dahlstron U, Lund LH. Association between RAS antagonist use and mortality in heart failure with severe kidney insufficiency: a prospective propensity score-matched cohort study. *Eur Heart J* 2015;**36**(34):2318–26.

51. Xu Y, El F, Trevisan M, Jemberg T, Sjolander A, Clase CM, Carrero JJ. Stopping renin-angiotensin system inhibitors after hyperkalaemia and risk of adverse outcomes. *Am Heart J* 2022;**243**:177–86.

52. Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, *et al*. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based Cohort study. *Am J Kidney Dis* 2022;**80**(2):164–173.e1.

53. Levy AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, *et al*. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. *Am J Kidney Dis* 2020;**75**:84–104.

54. Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, *et al*. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomised controlled trials. *J Am Soc Nephrol* 2019;**30**:1735–45.

55. Greene T, Ying Y, Vanesh EF, Tighiouart H, Levey AS, Coresh J, *et al*. Performance of eGFR slope as a surrogate endpoint for kidney disease progression in a clinical trial: a statistical simulation. *J Am Soc Nephrol* 2019;**30**:1756–69.

56. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, *et al*.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;**380**(24):2295–306.

57. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, *et al*.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med* 2020;**383**(15):1436–46.

58. Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, *et al*.; EMPA-REG OUTCOME Investigators. EMPA-REG OUTCOME Investigators. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. *J Am Soc Nephrol* 2018;**29**:2755–69.

59. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, *et al*.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;**383**:1413–24.

60. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Ramkumar N, Pappas LM, Cheung AK. Impact of timing of initiation of dialysis on mortality. *J Am Soc Nephrol* 2003;**14**:2305–12.

61. Fletcher BR, Damery S, Aiyegbusi OL, Anderson N, Calvert M, Cockwell P, *et al*. Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. *PLOS Med* 2022;**19**(4):e1003954.

62. Jain P, Cockwell P, Little J, Ferring M, Nicholas J, Richards N, *et al*. Survival and transplantation in end-stage renal disease: a prospective study of a multiethnic population. *Nephrol Dial Transplant* 2009;**24**(12):3840–6.

63. National Institute for Health and Care Excellence (NICE). *Chronic Kidney Disease: Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. National Institute for Health and Care Excellence CG73*. September 2008. URL: www.nice.org.uk/guidance/cg73 (accessed 2 September 2022).

64. Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, *et al*. Multicentre randomised controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. *Nephrol Dial Transplant* 2016;**31**(2):255–61.

65. Bhandari S, Mehta A, Khwaja A, Cleland JGF, Ives N, Brettell E, *et al*; for the STOP ACEi Trial Investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. *N Engl J Med* 2022;**387**(22):2021–32. https://doi.org/10.1056/NEJMoa2210639. Epub ahead of print.

66. National Institute for Health and Care Excellence (NICE). *Hypertension in Adults: Diagnosis and Management, NICE Guideline NG136*. August 2019. URL: www.nice.org.uk/guidance/ng136 (accessed 2 September 2022).

67. Al-Maqbali SRS, Mula-Abed Waad-Allah S, Mula-Abed W-AS. Comparison between three different equations for the estimation of glomerular filtration rate in Omani patients with type 2 diabetes mellitus. *Sultan Qaboos Univ Med J* 2014;**14**(2):e197–203.

68. Chesnaye NC, Dekker FW, Evans M, Caskey FJ, Torino C, Postorino M, *et al*. Renal function decline in older men and women with advanced chronic kidney disease-results from the EQUAL study. *Nephrol Dial Transplant* 2021;**36**(9):1656–63.

69. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero J-J, Chan W, *et al*. KDOQI clinical practice guideline for nutrition in CKD. *Am J Kidney Dis* 2020;**76**(3):S1–S107.

70. Jenna MN, Marva M, Eggers PW, Narva AS, Star RA, Kimmel PL, Rodgers GP. Social determinants of racial disparities in CKD. *J Am Soc Nephrol* 2016;**27**(9):2576–95.

71. Ricardo A, Yang W, Sha D, Appel LJ, Chen J, Krousel-Wood M, *et al*; on behalf of the CRIC Investigators. Sex-related disparities in CKD progression. *J Am Soc Nephrol* 2019;**30**(1):137–46.

72. Methven S, Steenkamp R, Fraser S. UK renal registry 19th annual report. *Nephron* 2017;**137**(Suppl 1):403–4.

73. Bukabau JB, Sumaili EK, Cavalier E, Pottel H, Kifakiou B, Nkodila A, *et al*. Performance of glomerular filtration rate estimation equations in Congolese healthy adults: the inopportunity of the ethnic correction. *PLOS ONE* 2018;**13**(3):e0193384.

74. Inker LA, Levey AS, Coresh J. Estimated glomerular filtration rate from a panel of filtration markers-hope for increased accuracy beyond measured glomerular filtration rate? *Adv Chronic Kidney Dis* 2018;**25**(1):67–75.

75. Gama RM, Clery A, Griffiths K, Heraghty N, Peters AM, Palmer K, *et al*. Estimated glomerular filtration rate equations in people of self-reported black ethnicity in the United Kingdom: inappropriate adjustment for ethnicity may lead to reduced access to care. *PLOS ONE* 2021;**16**(8):e0255869.

76. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, *et al*.; Chronic Kidney Disease Epidemiology Collaboration. Chronic kidney disease epidemiology collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med* 2021;**385**(19):1737–49.

EME
HSDR
HTA
PGfAR
PHR